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Abstract		
INTRODUCTION:	Radioiodine	ablation	therapy	with	Iodine-131	(I-131)	has	been	used	in	the	
treatment	of	hyperthyroidism	for	over	60	years.	Lithium,	a	drug	used	in	the	treatment	of	psychiatric	
disorders	is	known	to	accumulate	in	the	thyroid,	increasing	radioiodine	retention	by	blocking	its	release	
and	inhibiting	thyroid	hormone	release	without	affecting	thyroid	iodine	uptake.	
AIM:	To	compare	the	effect	of	adjuvant	lithium	therapy	on	the	efficacy	of	radioactive	iodine	therapy	in	
hyperthyroidism.	
Methods:	This	was	a	prospective	simple	randomised	comparative,	experimental	cohort	study	of	
hyperthyroid	patients	for	radioactive	ablation	therapy.	
Results:	Amongst	the	163	patients	submitted	for	final	analysis,	75	received	RAI	alone	whilst	88	
received	RAI	with	Lithium.	Those	who	received	RAI	with	adjuvant	lithium	showed	a	higher	cure	rate	
(78.4%)	compared	to	those	who	received	RAI	only	(68.1%)	(p	=	0.002).	At	1	month	post	RAI	therapy,	
27.4%	of	patients	who	received	RAI	with	adjuvant	therapy	were	cured	compared	to	just	14.5%	cure	rate	
in	those	who	received	RAI	alone,	a	trend	of	being	statistically	significant	(p	=	0.08)	and	indicating	a	faster	
cure	rate	for	patients	receiving	RAI	with	lithium.	Difference	in	mean	T4	concentration	at	3	months	
between	RAI	only	(17.67pmol/l)	and	RAI	with	Lithium	(11.55pmol/l)	was	significant	with	a	small	size	
effect	(U	=	2328.5,	Z	=	-2.700,	p	=	0.007,	r	=	0.01).	Also,	decrease	in	T4	concentration	from	baseline	to	
the	3	months	visit	in	both	groups	were	significant	(p	=	0.000	in	both	groups).	However,	significant	drop	
in	T4	concentrations	were	observed	between	the	baseline	and	1	month	visit	with	small	effect	size	(p	=	
0.001,	r	=	0.287)	patients	who	received	both	RAI	and	lithium.	
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CONCLUSION:		Adjuvant	lithium	therapy	increases	efficacy	of	radioactive	iodine	treatment	in	
hyperthyroidism	by	increasing	overall	cure	rate	and	also	shortening	the	time	to	cure.	
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1.	Introduction	
1.1.	Rationale	
Radioiodine	ablation	therapy	with	Iodine-131	(I-131)	for	hyperthyroidism	has	existed	for	over	60	years	
ever	since	Saul	Hetz	performed	the	first	RAI	treatment	of	Graves’	disease	on	31st	March	1941.	It	has	
been	used	widely	either	as	first	line	treatment	or	when	there	is	recurrence	or	persistence	of	
hyperthyroidism	after	a	course	of	antithyroid	drug	treatment.	The	goal	of	radioactive	Iodine	(RAI)	
treatment	is	a	stable	restoration	to	euthyroid	state	or	to	render	the	patient	permanently	hypothyroid.	
Provided	enough	radiation	is	deposited	in	the	thyroid	gland,	this	mode	of	therapy	is	highly	effective.	
Therefore,	any	intervention	that	seeks	to	increase	activity	and	or	uptake	of	the	radioactive	iodine	is	
most	likely	going	to	improve	the	efficacy	of	RAI	treatment.			
Lithium,	a	drug	used	in	psychiatric	disorders,	is	known	to	accumulate	in	the	thyroid.	When	given	
together	with	I-131,	it	increases	radioiodine	retention	by	blocking	its	release	and	inhibiting	thyroid	
hormone	release	without	affecting	thyroid	iodine	uptake.	A	blind	randomized	control	study	by	Bogazzi	
et	al	(1999)	demonstrated	that	a	short	course	of	lithium	therapy	given	concomitantly	with	RAI	resulted	
not	only	in	a	higher	cure	rate,	but	also	a	prompter	control	of	hyperthyroidism.		
This	study	aims	at	establishing	the	impact	of	adjuvant	Lithium	therapy	on	the	efficacy	of	RAI	in	
hyperthyroid	patients	from	a	heterogeneous	population	as	found	in	South	Africa.	
1.2. The	thyroid	Gland	
1.2.1. Brief	Anatomy	
Located	anteriorly	in	the	neck	at	the	level	of	the	C5—T1	vertebrae	and	lying	deep	to	the	sternothyroid	
and	sternohyoid	muscles,	the	thyroid	gland	primarily	comprise	of	right	and	left	lobes		anterolateral	to	
the	larynx	and	trachea	(1,	2).	These	lobes	are	joined	together	over	the	trachea,	by	a	relatively	thin	
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isthmus,	commonly	anterior	to	the	second	and	third	tracheal	rings.	A	thin	fibrous	capsule	surrounds	the	
thyroid	and		sends	septa	deeply	into	the	gland(1,	2).		These	septa	divide	the	gland	into	lobules	which	are	
made	of	large	numbers	of	closed	follicles	filled	with	a	secretory	substance	called	colloid	(3).	These	
follicles	are	also	lined	with	cuboidal	epithelial	cells	which	secrete	into	the	interior	of	the	follicles(3)	
The	normal	thyroid	in	an	adult	gland	weighs	between	15	to	20	g	with	the	lateral	lobes	measuring	about	
4	to	5	cm	from	superior	to	inferior	poles	and	are	1.5	to	2	cm	wide(4).	The	capsule	is	attached	to	the	
cricoid	cartilage	and	superior	tracheal	rings	by	dense	connective	tissue.		Normal	variations	in	the	
structure	of	the	thyroid	gland	include	the	presence	of	a	remnant	of	the	thyroglossal	duct	called	the	
pyramidal	lobe	which	is	found	in	approximately	50%	of	people	usually	above	the	isthmus	(1,	2,	4).		
The	well	vascularized	thyroid,	per	gram	of	tissue	of	any	organ,	has	one	of	the	highest	rates	of	blood	flow	
in	the	body(5)	.	It	has	a	rich	capillary	network	that	that	is	supplied	by	the	inferior	and	superior	thyroidal	
arteries	(2).	The	superior	thyroid	arteries	supplying	the	antero-superior	aspect	of	the	gland	usually	arise	
from	the	external	carotid	arteries.	The	inferior	thyroid	arteries	are	the	largest	branches	of	the	
thyrocervical	trunks	arising	from	the	subclavian	arteries	and	supply	the	postero-inferior	parts	of	the	
gland,	as	well	as	the	inferior	poles	(1,	2).		
A	thyroid	plexus	of	veins	is	usually	formed	on	the	anterior	surface	of	the	thyroid	by	superior,	middle	and	
inferior	thyroid	veins	which	respectively	drain	the	superior,	middle	and	inferior	poles.	The	superior	and	
middle	thyroid	veins	drain	into	the	internal	jugular	veins	and	the	inferior	thyroid	veins	drain	into	the	
brachiocephalic	veins(1,	2)	
1.2.2. Brief	Physiology	
Thyroxin	(T4)	is	the	primary	biologically	active		hormones	secreted	by	the	thyroid	(about	93%),	together		
with	lesser	quantities	of	triiodothyronine	(T3)	(about	7%)(3).	Both	these	hormones	are	amino	acids	
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which	contain	iodine.	Thyroxin	is	deiodinated	at	its	site	of	action	in	peripheral	tissues	to	the	much	more	
biologically	active	T3	(3,	5).	It	is	conceptually	helpful	to	see	T4	as	form	in	which	the	hormone	is	stored	
and	transported	and	T3	as	the	active	metabolic	form	(3).	Also	small	amounts	of	other	compounds,	
including	the	biologically	inactive	reverse	triiodothyronine	(3,	3',	5'-triiodothyronine,	RT3)	are	found	in	
thyroid	venous	blood(3).	
Iodine	is	very	important	for	normal	thyroid	function	as	it	is	a	very	critical	raw	material	for	thyroid	
hormone	synthesis.	Iodine	is	ingested	in	the	form	of	iodides	with	about	50mg	required	each	year,	or	
almost	1	mg/week	or	150ug	daily	for	normal	T4	production	in	adults	(3-5).	Iodides	ingested	orally	are	
absorbed	into	circulation	from	the	gastrointestinal	tract	in	the	same	manner	as	chlorides	(5).	Over	90%	
of	the	iodides	are	absorbed	systemically	within	60	minutes	of	ingestion.	Normally	a	fifth	of	the	ingested	
iodide	is	removed	from	circulation	and	used	in	thyroid	hormone	synthesis	whilst	the	rest	is	rapidly	
excreted	by	the	kidneys	(3-5).	
Iodine	is	transported	against	an	electrochemical	gradient	into	thyroid	follicular	cells	(3,	5).	The	
basolateral	membranes	of	the	thyroid	epithelial	cells	contain	Na+/I-	Symporter	(NIS)	which	transports	
two	Na+	ions	and	one	I-	ion	into	the	cell	against	the	electrochemical	gradient	for	I-,	with	each	cycle	(5).	
This	NIS	is	capable	of	producing	intracellular	iodine	concentrations	20	to	40	times	greater	than	plasma	
concentrations	involving	a	secondary	active	transport	process,	with	the	energy	provided	by	Na,	K	ATPase	
(5).	Regulation	of	the	NIS	is	by	transcription	and	also	by	active	trafficking	into	and	out	of	the	basolateral	
membrane	of	the	thyroid	epithelial	cells;	with	TSH	specifically	involved	in	the	induction	of	NIS	
expression	and	its	retention	in	the	basolateral	membrane	where	it	can	facilitate	continuous	iodide	
uptake(5).		
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Pendrin,	a	membrane-bound	iodide-chloride	transporter,	is	involved	in	transporting	the		iodine	through	
the	apical	membrane	of	the	cell	(3).	Thyroid	hormone	synthesis	begins	here	with	the	rapid	oxidation	of	
iodide	to	molecular	iodine,	promoted	by	the	thyroid	peroxidase	(TPO)	enzyme	and	the	accompanying	
hydrogen	peroxide.		In	the	thyroid	cells,	the	oxidized	iodine	is	associated	with	an	iodinase	enzyme	that	
causes	it	to	rapidly	bind	(within	seconds	or	minutes)	with	the	amino	acid	tyrosine	(3).	Thyroglobulin	(a	
molecule	containing	about	70	amino	acids)	is	synthesised	and	secreted	into	the	follicles	by	the	
endoplasmic	reticulum	and	Golgi	apparatus,	and	almost	immediately	iodine	binds	with	about	a	sixth	of	
the	tyrosine	within	the	thyroglobulin	molecule	(3,	5).	Tyrosine	is	first	iodized	to	monoiodotyrosine	and	
then	to	diiodotyrosine	followed	by	coupling	of	more	iodotyrosine	residues	in	minutes	up	to	even	the	
next	few	days	(3).	The	major	hormonal	product	of	the	coupling	reaction	is	thyroxine	or	T4	(coupling	of	2	
molecules	of	diiodotyrosine)		and	triiodotyrosine	or	T3	(coupling	one	molecule	of	monoiodotyrosine	
with	one	molecule	of	diiodotyrosine,	which	represents	just	about	a	fifteenth	of	the	final	hormones)(3,	
5).	Each	thyroglobulin	molecule	after	synthesis	of	the	thyroid	hormone	has	up	to	30	T4	molecules	and	
little	amounts	of	T3	molecules.	The	thyroid	gland,	usually	stores	enough	hormones	for	maintenance	of	
T4	and	T3	within	physiologic	serum	levels	for	at	least	2	weeks	to	about	3	months	(3,	5).		
Thyroglobulin	is	not	released	into	the	circulation	in	measurable	amounts;	T3	and	T4	are	released	as	free	
hormones	after	they	are	firstly	cleaved	from	the	thyroglobulin	molecule	(5).	In	response	to	TSH	
stimulation	the	apical	surface	of	the	thyroid	follicular	cell	sends	out	pseudopodal	extensions	that	form	
pinocytic	vesicles	by	closing	around	small	portions	of	the	colloid	which	then	migrate	to	the	apex	of	the	
thyroid	cells	(3).		Digestive	vesicles	are	produced	as	these	colloid	containing	vesicles	immediately	fused	
with	lysosomes	containing	digestive	enzymes.	Thyroxin	and	T3	are	then	released	in	the	free	form	after	
the	multiple	proteinases	among	the	enzymes	digest	the	thyroglobulin	molecules,	which	then	diffuse	into	
the	surrounding	capillaries	through	the	base	of	the	thyroid	cell	(3,	5).		
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The	process	of	thyroid	hormone	production	and	release	discussed	above	is	controlled	by	a	negative	
feedback	loop	in	which	thyrotropin-releasing	hormone	(TRH)	increases	secretion	of	TSH,	which	
stimulates	the	production	and	release	of	T4	and	T3	by	the	thyroid	gland,	and	both	hormones	in	turn	
inhibit	TRH	release	and	TSH	secretion	(3,	5).		
The	serum	half-life	of	the	thyroid	hormones	is	determined	by	how	strongly	they	are	bound	to	the	carrier	
proteins.	The	bond	between	T3	and	its	carrier	protein	is	fairly	weak,	hence	a	short	serum	half-life	of	
around	12	hours,	while	T4	has	a	lengthier	serum	half-life	of	almost	7	days	due	to	the	much	stronger	
bond	(3,	5).	These	carrier	proteins	consist	of	albumin	which	has	the	largest	binding	capacity	to	T4,	
transthyretin	(formerly	called	thyroxine-	binding	prealbumin),	and	thyroxin-binding	globulin	(TBG)	(3,	5).	
Thyroid	hormones	action	is	slow	at	onset	but	long	in	duration	(5).	About	80%	of	T4	is	converted	to	T3	by	
the	action	of	monodeiodinases	in	the	liver	and	other	tissues,	and	the	remaining	20%	is	conjugated	with	
glucuronide	and	sulphate	in	the	liver,	excreted	in	the	bile	and	partly	hydrolysed	in	the	bowel.	The	
deiodination	reactions	not	only	breaks	down	the	hormones,	but	also	to	specifically	provide	a	local	
supply	of	T3,	which	the	primary	facilitator	of	the	physiological	effects	of	secreted	thyroid	hormones(3,	
5).	
1.3. Thyrotoxicosis	
Thyrotoxicosis	is	a	disorder	having	multiple	aetiologies,	expressions,	and	potential	remedies	and	result	
from	unsuitably	high	thyroid	hormone	activity	in	tissues,	which	also	arises	from	elevated	thyroid	
hormone	levels	in	the	tissues	(6,	7).	Thyrotoxicosis	usually	refer	to	all	conditions	in	which	there	is	excess	
thyroid	hormone,	regardless	of	the	source	whilst	hyperthyroidism	on	the	other	hand,	refers	to	
conditions	in	which	thyroid	hormone	production	and	secretion	are	in	excess	(8,	9).	
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Hyperthyroidism	is	a	common	occurrence	with	population	prevalence	in	the	USA	for	example	at	1·2%	
(0.5%	overt	and	0.7%	subclinical)	(6)	whilst	in	Britain,	it	is	2%	in	women	and	0·2%	in	men(7).	In	the	
available	data	from	South	Africa,	Kalk	et	al	(1989)	also	suggested	a	lower	annual	incidence	of	
hyperthyroidism	(almost	10-fold)	in	black	population	(0.09	per	1000	women	and	0.007	per	1000	men)	
compared	to	whites	(10,	11).	In	Iodine	replete	communities	also,	hyperthyroidism	prevalence	is	10	times	
higher	in	women	(10).	The	incidence	among	women	in	the	USA	has	been	reported	as	0·38	per	1000	per	
year,	whilst	in	Scotland	the	figures	are	almost	doubled	at	0·77	per	1000	women	per	year	with	that	of	
men	standing	at	0·14	per	1000	per	year.	There	is	a	higher	incidence	in	white	population	and	in	iodine-
deficient	areas	and		increases	with	age(7).		
Thyrotoxicosis	in	general,	can	occur	if	there	is	inappropriate	stimulation	of	the	thyroid	by	trophic	factors	
or	autonomous	release	of	excess	thyroid	hormones	due	to	constitutive	activation	of	thyroid	hormone	
synthesis	(6,	7).	It	may	also	result	from	excessive	release	of	preformed	hormones	from	thyroid	stores	
due	to	autoimmune,	infective,	chemical	or	mechanical	injury	(6).	Finally,	it	can	arise	as	a	consequence	of	
exposure	to	extrathyroidal	sources	of	thyroid	hormone;	either	endogenously	(metastatic	differentiated	
thyroid	cancer,	struma	ovarii)	or	exogenously	(factitious	thyrotoxicosis)	(6).Table	1.1	gives	a	summary	of	
the	many	different	causes	of	thyrotoxicosis.		The	commonest	cause	of	thyrotoxicosis	is	Graves’	disease	
followed	by	autonomous	overproduction	of	thyroid	hormones	by	one	or	multiple	thyroid	nodules	
(solitary	toxic	adenoma	and	toxic	multinodular	goitre	respectively)	referred	to	as	Plummer’s	disease	by	
some	authors	(6,	7,	9).	A	brief	discussion	of	features	and	characteristics	of	these	common	causes	of	
hyperthyroidism	is	given	below.	
1.3.1. Graves’	disease	
This	is	an	autoimmune	disorder	where	autoantibodies	bind	to	and	stimulate	thyroid	stimulating	
hormone	(TSH)	receptors	found	on	the	surface	of	thyroid	follicular	cells,	resulting	in	overproduction	of	
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T4	and	T3	(6,	7,	12).	In	areas	of	sufficient	iodine	intake,	Graves’	disease	is	responsible	for	about	80%	of	
cases(7).	
The	etiology	of	Graves'	disease	involves	immunogenetic,	environmental	and	psychosocial	risk	factors	
with	smoking	an	important	trigger	in	several	underlying	processes.	It	is	thought	that	interaction	
between	intracellularly	processed	antigen,	MHC	class	I	molecules	and	CD8+	lymphocytes,	as	well	as	
MHC	class	II	molecules	and	CD4+	lymphocytes,	is	responsible	for	the	development	of	Graves'	
disease(12).	Subsequent	to	antigen	recognition,	CD4-	helper	T	lymphocytes	secrete	cytokines,	amplifying	
the	immune	reaction	by	activation	of	CD8+	T	lymphocytes	or	autoantibody-producing	B	cells	(12).	There	
is	suggestion	of	a	strong	genetic	influence	as	almost	half	of	people	with	Graves’	disease	have	a	close	
relation	with	some	thyroid	dysfunction	(13).	Also,	twin	concordance	studies	propose	up	to	80%	of	
susceptibility	being	ascribed	to	genetic	factors,	while	environmental	factors	may	be	responsible	for	the	
remaining		20%	(7,	12).		
Table	1.1:	Causes	of	thyrotoxicosis	and	hyperthyroidism*	
	 Pathogenic	Mechanism	
Common	causes	 	
Thyrotoxicosis	associated	with	hyperthyroidism	
Abnormal	thyroid	stimulator	production	
Graves’	disease	
Autonomous	Thyroid	
Toxic	multinodular	goitre	
Solitary	toxic	adenoma	
Thyrotoxicosis	not	associated	with	hyperthyroidism		
Inflammatory	disease	(thyroiditis)	
Silent	thyroiditis	(plus	post-partum)	
Subacute	thyroiditis	
Extrathyroidal	source	of	hormone	
Exogenous	thyroid	hormones	
	
	
TSH	receptor	antibody	stimulation	
	
Activating	G-proteins	or	TSH	receptor	mutations	
Benign	tumour,	autonomous	functioning	nodule	
	
	
Autoimmunity,	stored	hormone	release	
Likely	viral	infection	
	
Excess	thyroid	hormone	ingestion	(factitious	or	
iatrogenic)	
Uncommon	causes	 	
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Thyrotoxicosis	associated	with	hyperthyroidism	
Production	of	thyroid	stimulating	hormones	
TSH	secreting	pituitary	adenoma	
Pituitary	resistance	to	thyroid	hormone	
	
	
Neonatal	Graves’	disease	
Choriocarcinoma		
Hyperemesis	gravidarum	
Thyroid	autonomy	
Congenital	hyperthyroidism	
Struma	ovarii	
Metastatic	follicular	thyroid	carcinoma	
Drug-induced	hyperthyroidism	
Iodine,	),	radiographic	contrast	agents,	drugs	
containing	iodine	eg	Amiodarone	
Thyrotoxicosis	not	associated	with	hyperthyroidism	
Inflammatory	disease	
Thyroiditis	induced	by	drugs	such	as	lithium,	
Amiodaron	and		interferon	alpha	
Acute	infectious	thyroiditis	
Radiation	thyroiditis	
Thyroid	adenoma	infarction	
Extrathyroidal	source	of	hormone	
“hamburger”	thyrotoxicosis	
	
	
Pituitary	adenoma	
Thyroid	hormone	receptor-B	mutation	with	
better	expression	in	pituitary	than	in	peripheral	
tissues.	
Thyroid-stimulating	immunoglobulin	
HCG	secretion	
HCG	secretion	
	
TSH	receptor	mutation	activation	
Toxic	adenoma	in	an	ovarian	dermoid	tumour	
Foci	of	functional	autonomy	
	
Jod-Basedow	phenomenon	
	
	
	
Thyroid	follicle	destruction,	direct	effects	of	toxic	
drugs	
Infections	in	thyroid	(eg	bacteria,	fungal)	
Cellular	destruction	by	radioactive	iodine	
Stored	hormone	release	
1	
Consumption	of	contaminated	food	
	
Stimulating	antibodies	increase	hormone	secretion,	whereas	blocking	antibodies	inhibit	various	steps	in	
hormone	production.	Other	organs	can	be	affected	by	the	autoimmunogenic	process	in	Graves'	disease	
with	thyroid	eye	disease	being	the	most	significant	condition	and	often	co-exists	with	other	
autoimmune	diseases	such	as	rheumatoid	arthritis,	suggesting	possibly	a	shared	pathogenesis	(7,	12).	
Through	molecular	mimicry	of	the	TSH	receptor,	Yersinia	enterocolitica	infections	might	be	involved	in	
the	pathogenesis	of	Graves’	disease	(7)	
																																								 																				
*Adapted	from	Franklyn	et	al,	2012	
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1.3.2. Plummer’s	disease	
This	is	the	development	of	one	or	more	autonomous	cell	lines	that	hypersecrete	thyroxine	and	
triiodothyronine,	having	escaped	the	normal	feedback	control	mechanisms	resulting	in	either	a	solitary	
toxic	adenoma	or	toxic	multinodular	goitre	(7,	9,	12).	This	form	of	thyrotoxicosis	has	high	prevalence	in	
areas	where	endemic	iodine-deficiency	goitre	is	widespread	(7).	In	screening	studies,	up	to	40	–	50%	
prevalance	of	autonomy	has	been	found	in	iodine-deficient	areas.	In	contrast,	in	areas	without	iodine	
deficiency,	prevalence	is	very	low	(<	1%)	(7,	12).	Unlike	Graves'	disease,	which	affects	the	whole	thyroid	
gland	autonomy	is	mainly	a	focal	disease:	about	50%	are	multifocal,	25%	unifocal	and	25%	disseminated	
forms	of	autonomy.	Somatic	mutations	of	the	TSH	receptor	or	substances	responsible	for	receptor	
information	transmission	are	partly	the	cause	of	functional	autonomy(12).	
1.3.3. Clinical	presentation	
Excess	thyroid	hormone	affects	every	physiological	system	(table	1.2),	increasing	tissue	thermogenesis	
and	basal	metabolic	rate	(BMR)	as	well	as	reducing	systemic	vascular	resistance	and	levels	of	serum	
cholesterol	(5,	7,	12).	Interaction	of	intracellular	T3	with	nuclear	receptors	that	regulate	transcription	of	
many	different	genes	as	well	as	uptake	of	T3	by	specific	membrane	transporters	such	as	
monocarboxylate	transporter	are	responsible	for	these	effects	(5,	7,	8).	Triiodothyronine	also	display	
some	effects	that	are	non-genomic	with	excess	T3	also	enhancing	beta	adrenergic	receptor	activity	(5,	8)	
Symptoms	and	signs	of	the	cardiovascular	system	usually	dominate	with	tachycardia	and	
supraventricular	ectopic	activity	seen	in	patients	initially	with	healthy	hearts	(8).	One	of	the	most	serious	
complications	of	thyrotoxicosis	is	atrial	fibrillation,	which	is	an	independent	predictor	of	mortality	(7)	
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Table	1.2:	Signs	and	symptoms	of	thyrotoxicosis*	
	 Symptoms	 Signs		
Central	Nervous	System	 Tiredness,	nervousness,	anxiety,	
hyperactivity,poor	concentration	
Hyperactivity	
Hair	 hair	loss,	Thinning	 	
Eyes,	usually	in	Graves’	disease	 Pain,	grittiness	 Stare,	eyelid	retraction	and	lag,	
periorbital	oedema,	conjunctival	
injection,	ophthalmoplegia	
Thyroid		 Swelling	in	the	neck	 Goiter		
Muscle	 Tremor,	Weakness	 Fine	tremor,	muscle	wasting	
Skin		 Heat	intolerance,	increased	
perspiration	
Warm,	moist	skin.	Increased	
perspiration.		
Cardiovascular	System	 Palpitation,	shortness	of	breath	 Tachycardia,	atrial	arrhythmia,	
systolic	hypertension,	high	
output	heart	failure	
Gastrointestinal	System	 Weight	loss,	Increased	appetite	 Loss	of	weight2	
Peripheral	Nervous	System	 	 Hyperreflexia	
Reproductive	System	 	 Oligomenorrhoea,	decreased		
libido	and	fertility	
	
Graves'	disease	is	distinguished	clinically	from	other	forms	of	hyperthyroidism	by	the	existence	of	
diffuse	thyroid	enlargement,	ophthalmopathy	and	rarely	pretibial	myxoedema(14).	
Some	of	the	serious	complications	of	untreated	hyperthyroidism	consist	of	weight	loss,	atrial	fibrillation,	
osteoporosis,	embolic	events,	and	even	cardiovascular	collapse	and	death	(6).	
																																								 																				
*Adapted	from	Topliss	DI,	2010	and	Franklyn	et	al,	2012	
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In	summary,	all	patients	being	investigated	for	hyperthyroidism	must	have	a	comprehensive	history	
taken	and	undergo	a	thorough	physical	examination,	which	comprises	among	others	measurement	of	
body	weight,	pulse	rate,	respiratory	rate,	and	blood	pressure.	Also	thyroid	size,	tenderness,	symmetry	
and	nodularity	as	well	as	neuromuscular,	pulmonary	and,	cardiac	function;	and	presence	of	eye	signs,	
peripheral	edema,	or	pretibial	myxedema	should	be	assessed	(6).	
1.3.4. Laboratory	diagnosis	
Blood	TSH	measurement	has	the	greatest	sensitivity	for	thyrotoxicosis	diagnosis	and	is	the	most	suitable	
tool	for	screening	and	excluding	it.	Blood	TSH	is	undetectable	(normally	reported	as	<0·01	mIU/L)	in	
sensitive	assays	due	to	negative	feedback	of	thyroid	hormones	on	the	anterior	pituitary	(3,	6,	7).	
Thyroxin	concentration	measured	at	the	same	time	improves	diagnostic	accuracy(7).		
In	almost	all	cases	of	overt	hyperthyroidism,	free	T4	concentrations	are	raised	(3,	6).	In	cases	with	
normal	T4	and	supressed	TSH,	the	potential	for	T3	toxicosis	exists,	hence	free	or	total	T3	concentrations	
should	also	be	measured	(3,	5,	7).		
Subclinical	hyperthyroidism	is	defined	as	a	low	or	undetectable	serum	TSH	with	T3	and	T4	values	within	
estimates	for	the	normal	reference	range	(6).	Typical	signs	and	symptoms	may	arise	from	both	overt	and	
subclinical	disease.	
A	diagnosis	of	Graves’	hyperthyroidism	can	be	established	by	measurement	of	thyroid	stimulating	
hormone	receptor	(TSHR)	antibodies	though	the	test	is	not	widely	used.	Also	autoimmune	disease	can	
be	differentiated	from	toxic	nodular	hyperthyroidism	with	thyroid	peroxidase	antibodies	(anti-TPO)	
which	are	present	in	about	75%	of	cases	of	Graves’	hyperthyroidism	(7,	9).	
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1.3.5. Imaging		
Radioiodine	uptake	(RAIU)	in	the	thyroid	is	a	kinetic,	non-imaging	measurement	of	the	percentage	of	an	
administered	radioiodine	dose	incorporated	by	the	thyroid	over	a	standard	time	period,	an	individual	
measurement	representing	a	single	point	in	a	dynamic	process(9).		This	gives	a	useful	clinical	index	of	
thyroid	function	and	is	easily	performed.	The	goals	of	an	uptake	tests	before	RAI	treatment	are	to	
ensure	that	the	thyroid	will	take	up	radioactive	iodine	and	also	to	help	decide	how	much	activity	to	give	
during	treatment(4,	15).	Diagnosis	of	hyperthyroidism	or	hypothyroidism	is	a	biochemical	diagnosis	
made	solely	by	measurements	of	easily	serum	TSH		and/or	thyroid	hormones	hence	thyroid	uptake	
studies	not	useful	in	such		situations;	however,	it	may	be	useful	in	differentiating	Graves’	disease	from	
sub-acute	thyroiditis	or	factitious	hyperthyroidism	((4,	9,	15)as	demonstrated	in	figure	1.1	below.	
		
Figure	1.1.	Radioactive	Iodine	uptake	(RAIU)	for	diagnosing	the	aetiology	of	thyrotoxicosis.		
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Scintigraphy	is	necessary	in	all	patients	with	nodules	of	diameter	>	1	cm	and	is	indicated	also	in	patients	
with	smaller	nodules	if	there	are	signs	of	malignancy	or	functional	disorders(12)	Several	tracers	can	be	
used	for	scintigraphy	of	the	thyroid	gland.	Their	uptake	depends	largely	on	the	concentration	and	
activity	of	the	Na+/I-	symporter	(NIS)(12)	as	the		co-transport	mechanism	with	sodium,	due	to	the	
sodium	gradient	drives	the	iodine	transport	(9).	Iodine,	and	also	pertechnetate,	which	has	a	comparable	
molecular	size,	is	transported	into	the	follicular	cell	via	the	NIS.	Therefore,	I-123	and	99mTc-
pertechnetate	can	be	used	for	scintigraphy	and	I-131	for	therapy	(9,	12).		
The	indications	for	thyroid	scintigraphy	in	thyrotoxicosis	include:	
• Relating	the	thyroid	structure	to	function,	principally	in	distinguishing	Graves’	disease	from	toxic	
nodular	goitre.	Hyperthyroidism	results	in	an	increased	tracer	uptake,	either	iodine	or	
pertechnetate	as	shown	in	figure	1.2,	in	a	diffuse	pattern	(Graves’	disease)	or	a	heterogeneous	
or	nodular	pattern	(toxic	multinodular	goitre	and	toxic	adenoma).	This	distinction	is	important	in	
determining	therapeutic	radioiodine	dose	(4,	15,	16)	as	would	be	seen	later	on	in	this	chapter.	
• Determination	of	function	in	a	precise	area,	e.g.	in	the	assessment	of	a	palpable	nodule	for	
functionality	(4,	15)	
• Location	of	an	ectopic	thyroid	tissue(4,	15)	
• Differentiating	thyrotoxicosis	aetiology;	that	is,	Graves’	from	sub-acute,	silent	or	postpartum	
thyroiditis,	or	factitious	thyrotoxicosis.	The	latter	disorders	show	symptoms	of	mild	
hyperthyroidism	with	raised	serum	thyroid	hormones,	but	radioiodine	studies	reveal	low	RAI	
uptake	and	poor	visualization	(4,	9,	15,	16).	
1.3.6. Treatment		
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After	confirmation	of	hyperthyroidism,	a	choice	between	surgery,	radioiodine	therapy	and	antithyroid	
medications	is	required	(6,	7,	9).	Treatment	is	customised	to	the	individual	and	the	patient’s	age,	the	
presence	of	comorbidities,	goitre	size,	likelihood	of	remission	with	antithyroid	drugs	alone,	timing	of	
potential	future	pregnancies	and	patient	preference	ought	to	be	considered	(6,	9).	
a) b) c) 	
Figure	1.2.	Patterns	of	radioiodine	uptake	in	hyperthyroidism	in	selected	images	from	our	
local	archive;	a)	Graves’	disease,	b)	multinodular	goitre,	c)	toxic	adenoma.		
In	a	randomised	prospective	trial	comparing	treatment	outcomes,	patient	satisfaction	between	the	3	
modalities	was	90%,	with	no	difference	in	time	to	euthyroidism,	and	sick	leave	rates	also	remained	very	
similar	for	all	modalities	(17).		Patel	et	al	(2006)	also	demonstrated	similarities	in	long-term	quality	of	life	
for	all	treatment	choices,	although	RAI	exhibited		lowest	cost(18).	
1.4. Radioiodine	therapy	in	hyperthyroidism	
1.4.1. Physical	and	radiobiological	properties	of	radioiodine	
As	discussed	earlier,	iodine	is	an	essential	constituent	of	thyroid	hormones:	Thyroid	cells	extract	and	
concentrate	iodide	from	plasma.	Iodine-131	is	successfully	applied	in	the	therapy	of	patients	with	
hyperthyroidism	and	differentiated	thyroid	cancer.	Advantages	of	iodine	include:	good	tolerability,	
safety	and	efficacy	of	therapy	and	ease	of	application	(19,	20).	Iodine-131	is	currently	available	in	
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gelatine	capsules	and	drinking	solution	for	oral	use	as	well	as	in	intravenous	injections	as	sodium	iodide.	
At	each	passage	through	the	gland,	about	20%	of	the	circulating	iodide	is	removed	(19,	20).	
The	thyroid	gland	is	the	critical	organ	for	iodine	which	is	taken	up	by	the	thyroid	follicular	cells	within	
the	gland	(19).	Iodine	retention	in	the	cells	depends	on	the	cells’	metabolic	activity	(20).		The	thyroid	
takes	up	20-30%	of	ingested	iodine	in	normal	subjects,	with	up	to	70%	directly	excreted	in	the	urine	
(20).	In	hyperthyroid	patients	the	fraction	absorbed	by	the	thyroid	is	increased	to	even	more	than	90%	
in	extreme	cases	(4,	19,	20).	
	I-131,	employed	in	the	therapy	of	thyroid	disorders,	is	reactor	produced	from	the	fission	of	U-235	or	
neutron	irradiation	of	tellurium(21).	It	decays	to	stable	Xe-131	by	beta	emission.	The	physical	properties	
of	I-131(4,	19-21)	are	given	in	table	1.3	below.		With	regard	to	living	organisms,	the	biological	half-life	of	
iodine	in	the	thyroid	gland	(which	is	120	days)	should	be	taken	into	consideration.	Hence	the	effective	
half-life	in	the	living	body	is	calculated	to	be	7.6	days	(20).	
Iodine-131,	as	seen	in	table	1.3,	emits	two	types	of	radiation;	gamma	radiation	which	is	used	in	imaging	
and	beta	minus	(B-)	used	in	treatment	or	therapy.		For	I-131,	electron	penetration	in	soft	tissue	is	about	
1mm;	hence	the	energy	of	the	electron	radiation	is	absorbed	very	close	to	the	radiation	source.	Due	to	
this,	the	damaging	effect	of	beta	radiation	is	restricted	to	thyroid	cells	with	adjacent	cells	not	exposed	to	
significant	radiation	(20).	Radiobiological	effects	of	radioactive	iodine	on	tissues	are	either	direct	where	
radiation		is	deposited	inside	DNA		or	indirect,	which	leads	to	free	radical	production	that	in	turn	react	
with	essential	macromolecules(20)	
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Table1.3.	Physical	characteristics	of	I-131*	
Characteristics		 	
Physical	half-life	(t1/2)	 8.02	days	
Gamma	energy	 Energies	ranging	between	80	and	723kev	
364kev,(82%	abundance),	most	abundant	
Beta	emissions	
Maximum	energy	
Average		
	
0.606	Mev	(89%	abundance)	
0.192Mev	
Range	in	soft	tissue	
mean	
Maximum	
	
0.8mm	
3mm	
	
1.4.2. Clinical	indications	and	contraindications	in	hyperthyroidism	
The	clinical	indications	for	I-131	radioactive	iodine	therapy	in	hyperthyroidism	(4,	6,	19,	22)	include:	
• First	line	in	Graves’	dx	treatment	
• Autonomous	functioning	nodules	
• Relapsed	cases	of	hyperthyroidism	
• Persons	suffering	from	comorbidities	which		worsen	surgical	risk	
• Previously	operated	individuals	or	those	who	previously	received	radiation	to	the	neck	
• Unavailability	of	a	high-volume	thyroid	surgeon		
• Contraindications	or	allergy	to	antithyroid	drug	use	
• In	patients	with	malignant	ophthalmopathy	with	inactive	eye	disease,	used	for	ablation	of	
residual	thyroid	tissue	post-thyroidectomy.	
Multiple	considerations	go	into	decision	on	the	choice	of	therapy.		Together	with	the	patient,	an	
endocrinologist	should	carefully	appraise		the	treatment		risks	and	benefits	and	make	a	specific	
17	
	
recommendation;	with	the		final	decision	respecting	the	patients’		preferences	(23).	Patients	electing	for	
I-131	RAI	treatment	for	Graves’	disease	likely	place	a	relatively	higher	value	on	definitive	control	of	their	
hyperthyroidism,	the	potential	side	effects	of	antithyroid	medications	and	surgery,	as	well	as	a	relatively	
lower	premium	on	the	need	for	lifelong	thyroid	hormone	replacement,	potential	worsening	or	
development	of	Graves’	orbithopathy	and	the	rapid	resolution	of	hyperthyroidism	(6,	24).		
Absolute	contraindications	for	the	RAI	therapy	(6,	7,	16,	24)include:	
1. Pregnancy,	postpartum	and	lactation	
2. Small	children	without	appropriate	child	care	
3. Active	or	progressive	ophthalmopathy.	Glucocorticoid	therapy	used	to	prevent		worsening	of	mild	
thyroid	eye	disease	after	RAI	treatment	
4. Suspicion	of	associated	thyroid	malignancy.	Thyroid	nodules	therefore	should	be	assessed	prior	to	
RAI	treatment	to	exclude	malignancy	
5. Large	obstructive	goitre	
6. Inability	to	swallow	liquids	and/or	capsules;	
7. Inability	to	comply	with	radiation	precautions	and	safety	guidelines	
8. Females	planning	a	pregnancy	within	4–6	months	
9. Exposure	to	iodinated	CT	scan	contrast	within	the	prior	6	weeks.	
1.4.3.	Iodine-131	dose	selection	
The	main	aim	of	RAI	treatment	is	to	return	the	patient	to	a	euthyroidism,	with	or	without	T4	treatment	
(6,	7).	In	toxic	nodular	disease,	ablation	of	nodules	or	reduction	in	size	of	goitre	is	also	a	desired	goal	(6,	
7,	23).These	goals	are	achieved	equally	well	by	either	administering	a	calculated	dose	based	on	the	size	
of	the	thyroid	and	its	ability	to	trap	iodine	or	a	fixed	dose	of	radioactive	iodine.		Many	investigators	have	
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tried	several	techniques	to	calculate	the	radioiodine	dose	needed	to	render	patient	euthyroid	and	avoid	
hypothyroidism	based	on	factors	such	as	radioisotope	uptake	or	turnover	or	thyroid	size	(6,	7,	23).	
However,	the	use	of	a	calculated	dose	has	been	shown	to	have	no	advantages	over	a	fixed	dose	in	terms	
of	outcome	(22,	23,	25)and	apart	from	being	more	costly,	is	also	inconvenient	because	of	the	need	for	
extra	visits	and	investigations.	
1.4.4.	Factors	affecting	I-131	uptake	and	treatment	response	
Some	factors	have	been	shown	to	influence	the	outcome	of	radioiodine	treatment.	Individuals	with	
larger-volume	thyroid	glands	and	severe	hyperthyroidism	(13,	26)	have	demonstrated	a	greater	
likelihood	of	failure	to	respond	to	a	single	dose	of	RAI	(13,	14).	In	addition	to	the	dose	of	radioiodine	
administered,	these	clinical	factors	are	widely	viewed	as	the	most	reliable	predictors	of	response	to	
treatment	(13).	
In	an	audit	of	813	patients	treated	with	radioiodine,	Allahabadia	et	al.	demonstrated	amongst	others	,	a	
significantly	worse	outcome	after	RAI	treatment	in	males	compared	to	females,	despite	showing	a	
reduced	prevalence	of	palpable	goitre	(13).		
Antithyroid	drug	pre-treatment	is	also	known	to	affects	I-131	therapy	outcomes	(13,	27).		Pre-treatment	
with	propythiouracil	has	in	recent	studies	demonstrated	having	adverse	effects	on	cure	rate	post	RAI	
therapy	with	this	effect	appearing	to	persist	even	up	to	2	months	after	the	drug	is	stopped	prior	to	RAI	
administration	(13,	27,	28).	The	thionamides	on	the	other	hand	appear	to	have	no	apparent	adverse	
effect	on	cure	rate,	provided	the	drug	is	stopped	at	least	a	day	before	radioiodine	treatment	is	given	(6,	
27,	28)	though	minimum	of	3-5	days	usually	advised.	
Other	factors	which	have	been	shown	to	affect	I-131	therapy	outcomes	include	the	24	hour	radioactive	
iodine	uptake	(which	gives	an	indication	of	the	residence	tie	of	the	radioactive	iodine	in	the	thyroid),	age	
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of	the	patient(greater	risk	of	failed	treatment	in	the	young)(29),	and	the	presence	or	absence	of	nodules	
in	the	goitre	(13,	30)	as	well	as	other	iodine	containing	medications	and	preparation	(	eg.	Amiodarone,	
intravenous	contrast)	that	are	used	close	to	therapy	(4,	16)	
1.5.	Lithium	and	the	thyroid	
In	1967,	at	a	conference	in	Denmark,	incidence	of	goitre	in	patients	receiving	lithium	was	cited	and	
these	data	published	in	the	British	Medical	Journal	in	1968(31).	The	physiology	and	clinical	effect	of	
lithium	on	the	thyroid	since	then	has	been	significantly	studied.	
Lithium	a	drug	used	in	treatment	of	psychiatric	disorders	like	manic-depressive	psychosis	and	for	
prophylaxis	of	bipolar	affective	disorders(32).		It	is	also	used	both	in	augmenting	treatment	of	
depression	and	in	some	cases	of	unipolar	depression	(33).			Through	its	inhibitory	effects	on	the	activity	
of	adenosine	triphosphatase	(ATPase),	cyclic	adenosine	monophosphate	(cAMP)	as	well	as	intracellular	
enzymes,	Lithium	affects	cell	function	(33,	34).	Also,	signal	transduction	is	affected	by	the	inhibitory	
effect	of	lithium	on	inositol	phospholipid	metabolism	which		partly	accounts	for	some	of	its	action	in	
manic	depression	(33),	i.e.,	prophylactic	prevention	of	recurrent	mania	as	well	as	recurrent	depression.		
Lithium	is	rapidly	absorbed	from	the	gastro-intestinal	system	as	a	simple	cation	unbound	to	tissue	
proteins	or	plasma,	with	almost		95%	of	a	given	dose	excreted	unchanged	via	the	kidneys	in	24	hours	
(34).	
Serious	side	effects	from	taking	lithium	are	rare	however;	minor	complaints	such	as	diarrhoea,	nausea,	
gastrointestinal	discomfort,	weight	gain,	skin	eruptions,	polyuria,	alopecia,	and	edema	are	common.	
Significant	nephrotoxicity	does	not	usually	occur	though	urine-concentrating	abilities	may	be	decreased	
(34).		Some	of	the	more	severe	side	effects	consist	of	poor	concentration	and	memory,	ataxia,	tremor,	
dysarthria,	and	incoordination	(34,	35).	
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1.5.1.	Effect	of	Lithium	on	thyroid	physiology	
Lithium	has	several	effects	on	the	physiology	of	the	thyroid.	Contributing	to	this	picture	is	the	receptor	
mediated	mechanism	of	thyroid	hormone	activity	as	well	as	the	autonomous	effects	of	the	
hypothalamic–pituitary–thyroid	axis	(33,	36).	Though	the	mechanism	of	action	is	still	not	clear,	it	is	
thought	that	the	intracellular	disturbances	that	occur	can	be	explained	partly	by	the	inhibition	of	cyclic	
AMP-mediated	cellular	events	by	lithium	and	also	by	the	resultant	inhibitory	actions	on	the	
phosphoinositol	pathway	(33,	36).	Lithium	also	has	immunological	effect	on	thyroid	antibody	levels	
which	leads	to	a	faster	inception	of	thyroid	autoimmunity	usually	characterised	by	goitre	and	
hypothyroidism	but	also	with	the	possibility	in	some	situations	of	hyperthyroidism	(33,	36).	
The	most	essential	clinically	relevant	action	of	lithium	especially	for	purposes	of	this	study	is	probably		
the	inhibition	of	the	release	of	thyroid	hormones	which	result	in	the	development	of	hypothyroidism	
and	goitre	(36).	There	is	a	surge	in	TSH	concentration	due	to	the	earlier	inhibition	of	thyroid	hormone	
release	resulting	in	thyromegaly.	Also,	lithium	acts	by	altering	signal	transduction	within	the	cell	and	the	
function	of	insulin-like	growth	factor	as	well	as	activation	of	a	tyrosine	kinase	to	encourage	the	
proliferation	of	cell	(33,	36)	which	further	potentiates	its	hypothyroidal		and	goitrogenic	effect.	The	
inhibition	of	thyroid	hormone	release	is	also	linked	to	the	Lithium	associated	hypothyroidism		and	may	
occur	in	patients	with	or	without	a	goitre	(36).		However	hyperthyroidism	have	been	reported	in	
significant	numbers,	despite	generally	the	suppressive	actions	of	lithium	on	the	function	of	the	thyroid	
(36).	
Other	thyroidal	effects	of	lithium	include	impaired	iodination	of	thyroglobulin	and	peripheral	
deiodination	of	T4	(30,	32).	Direct	inhibitory	effects	of	lithium	on	the	synthesis	and	secretion	of	thyroid	
hormones	can	result	in	a	compensatory	increase	in	serum	TSH.	
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Lithium	is	also	known	to	inhibit	colloid	formation,	and	involved	in	blocking	organic	iodine	as	well	as	
thyroid	hormone	release	from	the	thyroid	gland	without	an	effect	on	the	radioiodine	uptake	(30,	32,	
35).	This	directly	leads	to	increased	radioiodine	retention	in	the	thyroid	gland.		
Due	to	its	potency	as	a	thyroid	hormone	inhibitor,	it	was	just	a	matter	of	time	that	attempts	were	
initiated	to	assess	its	effectiveness	in	management	of	thyrotoxicosis.	Early	studies	(36,	37)	showed	
satisfactory	reduction	in	thyroid	hormone	levels,	however	a	randomised	trial	by	Kristensen		et	al	(38)	
failed	to	demonstrate	lithium	as	better	than	thionamides	in	therapy	for	thyrotoxicosis.		Another	study	
established	that	in	individuals	who	showed	poor	tolerance	or	response	to	thionamides,	low	dose	lithium	
was	a	fairly	safe	and	effective	substitute	in	controlling	thyrotoxicosis	(39).	In	very	severe	incidents	of	
thyrotoxicosis,	it	is	particularly	useful	when	add	to	thionamide	therapy	(36).	
Though	the	physiologic	and	clinical	actions	of	lithium	on	the	thyroid	suggest	its	effectiveness	as	an	
adjunct	to	radioiodine	therapy,	there	are	however	conflicting	reports	on	the	ground.			
The	first	to	suggest	lithium	as	an	adjunct	therapy	in	hyperthyroidism	with	radioiodine,	Turner	et	al.	in	
1976,	recognised	an	increased	thyroidal	retention	of	I-131	in	their	patients	(40).	The	Pisa	group	in	Italy,	
showed	in	two	large	randomised	trials	that	lithium	improved	the	efficacy	of	I-131	therapy	by	a	prompter	
control	of	the	disease	and	in	patients	with	large	goitres,	improving	the	rate	of	permanent	control	(30,	
41)	This	group	also	showed	that	adjuvant	lithium	given	at	the	time	of	treatment		prevented	the	increase	
in	thyroid	hormone	concentrations	associated	with	anti-thyroid	drug	withdrawal	and	131I	
administration(41).	Results	from	a	cohort	study	by	this	same	group	on	Graves’	disease	patients	in	2010	
not	only	confirmed	or	supported	the	above,	but	also	showed	a	greater	cure	rate	of	patients	treated	with	
RAI	plus	lithium	(91%)	as	against	RAI	alone	(85%,	P	=	0.030)after	1	year(35).		Martin	et	al	(42)	also	
demonstrated	improvement	in	efficacy	of	RAI	with	adjuvant	lithium	in	both	Grave’s	and	toxic	nodular	
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goitre		by	a	9%	higher	cure	rate	after	a	year	follow-up,	significant	reduction	in	time	to	achieve	cure	and	
significant	reduction	in	T4	(12%)	and	T3	(17%)	concentrations.		
However	in	another		randomised	controlled	study	involving	350	hyperthyroid	patients	(43),	no	
statistically	significant	difference	was	observed	in	response		between	those	receiving	RAI	alone	and	RAI	
with	adjuvant	Lithium.	Even	in	patients	with	glands	that	are	discharging	rapidly	or	have	large	goitre,	no	
statistically	significant	difference	was	observed	in	RAI	treatment	outcome	between	the	2	groups(43).	
Though	Zha	et	al	(44)	showed	cure	of	hyperthyroidism	was	achieved	in	72%	of	patients	treated	with	I-
131	alone	and	in	76%	patients	treated	with	I-131	plus	lithium;	this	did	not	differ	significantly	at	the	end	
of	the	study	(p	>	0.05).	While	lithium	may	not	affect	the	outcome	of	radioiodine	therapy	in	the	long	
term,	it	may	be	beneficial	in	therapy	in	patients	with	a	very	short	effective	half-life	of	the	isotope	to	
reduce	the	activity	required	and	the	whole-body	radiation	dose	(44,	45).	Using	lithium	as	adjunct	to	
radioiodine	therapy	improves	the	radiation	dose	delivered	to	the	thyroid	by	39%	on	average	and	nearly	
30%	of	radioiodine	activity	can	be	saved	in	these	patients(45).	It	may	also	be	employed	in	the	
radioiodine	treatment	of	multi-nodular	goitre	where	it	has	been	shown	to	reduce	radioiodine-induced	
hyperthyroidism,	thus	making	iodine-131	therapy	safer	in	the	elderly	patient	who	may	have	
cardiovascular	disease	(46).	
1.6.	Problem	statement	
On	the	average	30	to	40	patients	are	treated	every	month	with	RAI	for	hyperthyroidism	at	the	Charlotte	
Maxeke	Johannesburg	Academic	Hospital	(CMJAH)	and	Chris	Hani	Baragwanath	Academic	Hospital	
(CHBAH).	This	includes	patients	who	are	reporting	for	second	dose	of	RAI	following	an	unsuccessful	
previous	treatment.	
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In	a	study	presented	over	a	decade	ago,	the	nuclear	medicine	group	at	the	Johannesburg	hospital	noted	
treatment	failure	or	persistence	of	hyperthyroidism	in	about	10%	of	805	patients	who	received	RAI	(47).	
Generally,	literature	reports	between	10	and	20%	treatment	failure	(35,	48).	A	long	term	follow-up	study	
by	Metso	et	al	showed	that	in	25%	of	patients,	two	to	six	RAI	treatments	were	needed	to	achieve	either	
a	hypothyroid	or	a	euthyroid	state(49).	Also,	retreatment	with	radioiodine	was	necessary	in	10	–	30%	of	
patients	with	toxic	adenoma	and	6	to	18%	of	those	with	toxic	multinodular	goitre	(23).This	has	therefore	
led	to	the	quest	for	cheaper	and	more	effective	ways	of	improving	efficacy	of	RAI.		
The	effects	of	lithium	on	the	thyroid	gland	as	stated	earlier	in	this	text,	as	well	as	other	studies	carried	
out	led	to	the	postulation	of	the	problem	statement:	Does	Lithium	administered	as	an	adjuvant	therapy	
to	radioactive	iodine	improve	its	efficacy	in	hyperthyroid	patients?	
1.7.	Aim	
To	compare	the	effect	of	adjuvant	lithium	therapy	on	the	efficacy	of	radioactive	iodine	therapy	in	
hyperthyroidism.	
1.8.	Study	objectives	
The	objectives	of	this	study	include:	
a. To	compare	the	effectiveness	of	radioactive	iodine	combined	with	lithium	versus	radioactive	
iodine	alone	in	the	treatment	of	hyperthyroidism.	
b. Establish	whether	there	is	significant	difference	in	results	obtained	for	the	two	groups.	
c. To	modify	whenever	possible	current	management	protocol	for	patients	receiving	RAI	locally.	
2.	Subjects	and	methods	
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2.1.	Study	design	
This	was	a	prospective	simple	randomised	comparative,	experimental	cohort	study	of	hyperthyroid	
patients	for	radioactive	ablation	therapy.				
2.2.	Study	population		
The	study	included	185	hyperthyroid	patients	referred	to	the	Departments	of	Nuclear	Medicine	and	
Molecular	Imaging	of	both	the	Charlotte	Maxeke	Johannesburg	Academic	Hospital	(CMJAH)	and	Chris	
Hani	Baragwanath	Academic	Hospital	(CHBAH)	between	February	2014	and	September	2015.	
2.2.1.	Inclusion	criteria	
Hyperthyroid	patients,	both	Graves’	disease	and	Plummer’s	disease	patients	referred	for	Radioactive	
Iodine	131	ablation.	
2.2.2.	Exclusion	criteria	
The	following	patients	were	excluded	from	the	study.	
1. Patients	who	decline	the	request	to	participate	in	the	study	
2. Patients	with	active	ophthalmopathy	
3. Psychiatric	patients	and	those	already	on	lithium	treatment	
4. Patients	with	contraindications	to	lithium	therapy	such	as;	
a. Lithium	allergy	
b. Renal	dysfunction	
c. Cardiac	dysfunction		
d. Prolonged	QT	intervals	
2.3.	Methods	
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Hyperthyroid	patients	referred	for	radioactive	Iodine	ablation	were	approached	to	enter	the	study.	After	
thorough	explanation	of	the	study,	those	who	volunteered	to	take	part	were	made	to	sign	consent.		
The	aetiology	of	hyperthyroidism	in	all	patients	was	established	based	on	the	clinical	history	and	
physical	examination,	biochemical	profile	(TSH,	TSH	receptor	antibody),	thyroid	sonography	and/or	
scintigraphic	imaging	of	the	thyroid.	The	clinical	history	and	examination,	as	well	as	serum	urea	and	
creatinine	in	some	cases,	also	helped	exclude	patients	who	fell	short	of	the	inclusion	criteria.	All	patients	
had	a	thyroid	scan	confirming	hyperthyroidism	before	treatment	with	radioactive	iodine.		
2.3.1.	Treatment	
Some	patients	were	pretreated	with	neomercazole.	This	was	withdrawn	at	least	5	–	7	days	before	the	
RAI	treatment.	The	patients	who	met	the	eligibility	criteria	were	put	into	two	parallel	groups	on	the	day	
of	treatment;	
1. The	first	group	was	the	control	group	which	received	fixed	dose	of	radioactive	iodine-131	only		
2. The	second	group	receiving	fixed	dose	of	radioactive	iodine-131	plus	Lithium	carbonate	(800mg)	
daily	for	7	days,	starting	from	day	of	RAI	administration.	The	lithium	was	started	on	the	day	of	
radioactive	iodine	administration	firstly	to	reduce	the	number	of	hospital	visits	and	also	for	
convenience	of	patients	as	some	of	the	patients	were	referred	from	outlying	hospitals	
Dose	of	radioactive	iodine	given	was	10mCi	for	Graves’	disease,	20mCi	in	two	weekly	fractionated	doses	
for	toxic	adenoma	and	30mCi	in	three	weekly	fractionated	doses	for	toxic	multinodular	goitre.	
2.3.2. Follow-up	
All	patients	were	followed	up	for	three	months	(12	weeks)	from	date	RAI	was	administered,	which	was	
selected	as	the	first	day.	The	end	point	of	3	months	was	based	on	findings	that	hyperthyroid	patients	
who	fail	to	respond	to	RAI	therapy	after	3	months	can	be	retreated	as	treatment	failure	can	be	assumed	
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in	such	circumstances	(6,	50,	51)		As	the	aim	was	not	to	interfere	with	the	normal	or	routine	clinic	
follow-ups,	patients	were	reviewed	at	the	endocrine	clinics	at	4	–	6	weeks	and	at	12	weeks	post	ablation	
with	thyroid	functions	(TSH,	T4	and/or	T3)	as	is	the	protocol	in	the	hospitals	involved.	All	the	blood	tests	
were	done	at	the	National	Health	Laboratory	Services	(NHLS)	and	results	were	assessed	through	their	
database.	
2.3.3. Definition	of	Cure	
	Cure	was	defined	as	the	achievement	of	euthyroidal	or	hypothyroidal	state	3	months	post	RAI	therapy.	
Normal	range	values	for	TSH,	T4	and	T3	were	based	on	the	values	defined	by	the	NHLS	which	are	given	
below:	
1. TSH	normal	range:	0.35	–	5.50mIU/L.		Patient	is	hyperthyroid	when		TSH	is	less	than	0.35mIU/L		
and	hypothyroid	when	TSH	is	greater	than	5.50mIU/L	
2. Free	T4	normal	range:	11.5	–	22.0	pmol/L	
3. T3	normal	range:	3.1	–	6.6	pmol/L	
2.4.	Data	collection	
Data	on	the	patients	were	collected	and	displayed	on	the	data	collection	sheet	shown	in	appendix	A.	
All	the	information	inputted	into	the	data	collection	sheet	was	obtained	from	history	taken	from	the	
patient,	patient’s	hospital	records	and	results	from	the	NHLS	trackcare	system.	
2.5.	Bias		
All	patients	involved	in	the	study	were	known	to	be	hyperthyroid	and	the	type	of	hyperthyroidism	
(Graves’	disease	or	Plummer’s’	disease)	was	known.	Selection	of	patients	into	the	different	arms	of	the	
study	was	done	by	simple	randomisation.		On	day	of	treatment	every	other	patient	received	RAI	with	
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adjuvant	lithium.	The	doctor	administering	the	capsules	on	the	day	decides	which	group	(RAI	only	or	RAI	
with	adjuvant	lithium)	to	put	the	first	patient	to	be	treated	on	the	day.	No	factors	were	considered	in	
deciding	which	patient	enters	which	arm	of	the	study	eliminating	all	possible	biases	in	patient	selection.	
2.6.	Statistical	analysis	
Data	was	analysed	using	SPSS.	Results	were	presented	as	mean+/-	SD	for	normal	distribution	and	for	
skewed	distribution	as	median.	Baseline	values	were	expressed	as	percentages	for	qualitative	variables	
and	for	quantitative	variables	as	mean	+/-	SD.	The	baseline	characteristics	of	the	two	groups	(RAI	only	
and	RAI	with	adjuvant	Lithium)	were	compared	by	nonparametric	Mann-Witney	test	for	quantitative	
variables	or	by	the	Pearson	Chi-square	test	or	Fisher’s	exact	test	for	qualitative	variables	where	
applicable.	
The	time	trend	of	serum	T4	concentration	in	the	two	treatment	groups	were	compared	using	the	
Wilcoxon	Signed	rank	test	and	the	Freidman	test.	
2.7.	Ethics	
The	study	was	approved	by	the	Human	Research	Ethics	Committee	of	the	University	of	the	
Witwatersrand,	clearance	certificate	number	M130846.	This	certificate	is	attached	as	Appendix	B.	
2.8.	Data	safety	
Patient’s	anonymity	was	ensured	using	assigned	study	numbers	or	codes.	The	key	to	decipher	the	
number	codes	were	kept	in	a	secure	location	known	only	to	the	primary	investigator.	Several	back-up	
versions	of	the	data	were	kept	at	all	times	to	prevent	loss	of	information	due	to	data	corruption	and	
these	were	kept	in	on	storage	devices	with	password	protection.	
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3. Results		
	
A	total	of	185	patients	were	recruited	to	be	part	of	this	study.	Out	of	this	number;	
• 163	patients	met	the	inclusion	criteria	and	had	reached	the	end	point	at	the	time	of	data	
analysis.	
• 1	patient	was	dropped	from	the	study	due	to	symptoms	suggestive	of	lithium	side	effects.	
• Another	2	patients	were	excluded	due	to	them	being	hypothyroid	and	euthyroid	at	the	time	of	
RAI	treatment	(i.e.	TSH	>	0.35)	
• 10	patients	were	lost	to	follow-up	and	hence	no	TFT	results	were	available	from		3	months	
• 9	patients	recruited	had	not	reached	endpoint	at	the	time	of	data	analysis.	
3.1.	Dermographics		
Amongst	the	163	patients	submitted	for	final	analysis,	75	received	RAI	alone	whilst	88	received	RAI	with	
Lithium.	Baseline	clinical	and	biochemical	findings	of	these	two	groups	of	patients	are	shown	in	table	
3.1.	Generally,	the	two	treatment	groups	did	not	differ	in	their	main	clinical	and	biochemical	features.	
Table3.1.	Baseline	clinical	and	biochemical	features	of	patients	received	RAI	alone	and	
patients	who	received	RAI	with	adjuvant	Lithium.	
Features		 RAI	Only	 RAI	+	Lithuim	 P-value	
Patients	(M/F)	 75	(11/64)	 88	(9/79)	 0.6545	
Mean	age	+/-	SD	 48.40	+/-	12.04	 43.68	+/-13.24	 1.0000	
Graves’	disease	 62	(83%)	 72	(82%)	 1.0000	
Toxic	nodular	disease	 13	(17%)	 16	(18%)	 1.0000	
Pretreatment	with	ATDs	 55	(57%)	 42	(43%)	 0.6605	
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Mean	T4	at	V1	(pmol/l)	 33.72	+/-	20.50	 34.83	+/-24.55	 0.637	
Mean	TSH	(mIU/l)	 0.04	 0.05	 0.253	
	
3.2.	Cure	rate	
Table	3.2	demonstrates	the	distribution	of	patients	according	to	those	who	got	cured	and	those	who	
remained	hyperthyroid	at	the	endpoint	of	the	study	in	the	two	main	groups	(RAI	only	and	RAI	and	
Lithium).	Out	of	the	total	163	patients	enrolled,	111	(68.1%)	got	cured	(i.e.euthyroid	or	hypothyroid)	3	
months	post	RAI	therapy	which	was	the	end	point	of	the	study	whilst	52	(39.1%)	remained	hyperthyroid.	
For	the	patients	who	received	RAI	only,	42	making	56%	were	cured	whilst	33	patients	(44%)	remained	
hyperthyroid	after	3	months.	In	the	patients	who	received	RAI	with	adjuvant	Lithium	therapy	however,	
78.4%	(69	patients)	got	cured	whilst	only	21.6%	(19	patients)	remained	hyperthyroid	at	the	endpoint	of	
the	study.	This	represents	a	significant	increase	in	percentage	of	patients’	cured	(22.4	percentage	
points)	in	those	who	received	RAI	with	adjuvant	lithium	therapy	over	the	patients	who	received	RAI	only	
(p	=	0.002).		
Table	3.2.	Number/proportion	of	patients	cured	at	3	months	post-RAI	therapy.		
	 No	Cure	
(Hyperthyroid	)	
Cured	
(Euthyroid+hypothyroid)	
Total		
RAI	Only		
	
33	
44%	
42	
56%	
75	
100%	
RAI	+	Lithium	 19	
21.6%%	
69	
78.4%	
88	
100%	
Total		 52	
39.1%	
111	
68.1%	
163	
100%	
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At	1	month	post	RAI	therapy,	27.4%	of	patients	who	received	RAI	with	adjuvant	therapy	were	cured	
compared	to	just	14.5%	cure	rate	in	those	who	received	RAI	alone	as	seen	in	figure	3.1.		This	12.9%	
difference	in	cure	rates	however	showed	a	trend	of	being	statistically	significant	(p	=	0.08).	
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Figure	3.1.	Graph	showing	percentage	of	patients	who	were	cured	and	those	who	remained	
hyperthyroid	(no	cure)	1	month	post-ablation.	
Table	3.3	gives	a	breakdown	of	the	number	of	patients	who	were	cured	after	RAI	only	or	RAI	with	
adjuvant	lithium	therapy	at	3	months	according	to	diagnosis.	
For	Graves’	patients,	there	was	a	statistically	significant	increase	of	22.1%	in	cure	rate	when	patients	
who	had	RAI	with	adjuvant	lithium	where	compared	with	patients	who	received	RAI	only	(p	=	0.012)	as	
illustrated	in	figure	3.2.	This	shows	an	association,	with	a	small	effect	size,	between	adjuvant	lithium	
therapy	and	increased	cure	rate	in	Graves’	disease	patients	(Phi	=	0.235,	p	=	0.007).		
In	nodular	disease	patients	(table	3.3,	figure	3.3),	though	there	was	an	increase	in	cure	rate	of	11.2%	in	
patients	who	received	RAI	with	adjuvant	lithium	over	RAI	alone,	this	was	not	statistically	significant	(p	=	
0.151).	
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Table	3.3.	Proportion	of	patients	cured	at	end	of	study	grouped	by	diagnosis	
Diagnosis		 Treatment		 No	cure		 Cure		 Total		
Graves’	disease		 RAI	only	 27	
44.3%	
34	
55.7%	
61	
100%	
RAI	+	Lithium	 16	
22.2%	
56	
77.8%	
72	
100%	
Total		 43	
32.3%	
90	
67.7%	
133	
100%	
Nodular	disease	 RAI	only	 6	
42.9%	
8	
57.1	
14	
100%	
RAI+	Lithium	 3	
18.2%	
13	
81.2%	
16	
100%	
Total	 9	
30.0%	
21	
70.0%	
30	
100%	
	
	
Figure	3.2.	Graph	showing	response	to	therapy	at	3	months	for	patients	with	Graves’	disease.	
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Figure	3.3.	Graph	showing	response	to	therapy	at	3	months	for	patients	with	nodular	
disease.	
	
Table	3.4	illustrates	the	distribution	of	patients	post	RAI	only	and	RAI	with	adjuvant	Lithium	grouped	by	
gender	3	months	post-therapy.		
Female	patients	who	received	RAI	with	adjuvant	Lithium	therapy	had	significantly	higher	cure	rates	
(78.5%)	compared	with	those	who	received	RAI	alone	(53.1%)	(p	=	0.001).	The	25.4%	increase	in	patients	
cured	who	received	adjuvant	lithium	highlights	the	association	(with	a	small	effect	size)	of	adjuvant	
Lithium	and	female	sex	with	higher	cure	post	RAI	therapy	(Phi	=	0.268,	p	=	0.001).	
There	was	no	statistically	significant	difference	in	cure	rates	between	male	patient	who	received	RAI	
with	adjuvant	Lithium	(77.8	%)	and	those	who	received	RAI	alone	(72.7%)	(p	=0.795)	
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Table	3.4.	Proportion	of	patients	cured	at	end	of	study	grouped	by	gender	
Gender	 Treatment		 No	cure		 Cure		 Total		
Female		 RAI	only	 30	
46.9%	
34	
53.1%	
64	
100%	
RAI	+	Lithium	 17	
21.5%	
62	
78.5%	
79	
100%	
Total		 47	
32.9%	
96	
67.1%	
143	
100%	
Male		 RAI	only	 3	
27.3%	
8	
72.7	
11	
100%	
RAI+	Lithium	 2	
22.2%	
7	
77.8%	
9	
100%	
Total	 5	
25%	
15	
75.0%	
20	
100%	
	3.3.	Thyroid	hormone	concentration	
Figure	3.4	shows	serum	free	T4	concentrations	in	patients	who	received	RAI	only	and	those	who	
received	RAI	with	lithium	at	baseline	(V1),	1	month	(V2)	and	3	months	(V3)	post	treatment.	
	
Figure3.4.	Mean	T4	concentration	between	the	RAI	only	and	RAI	with	Lithium	groups	over	
the	3	visits.	
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There	was	no	statistically	significant	difference	in	mean	free	T4	concentration	between	the	two	groups	
at	baseline	(U	=2977,	Z	=	-0.415,	p	=0.678,	r	=	0.003)	and	1month	post-treatment	(U	=	1611.5,	Z	=	-1.282,	
p	=	0.200,	r	=0.01).	However,	difference	in	mean	T4	concentration	at	3	months	between	RAI	only	
(17.67pmol/l)	and	RAI	with	Lithium	(11.55pmol/l)	was	significant	with	a	small	size	effect	(U	=	2328.5,	Z	=	
-2.700,	p	=	0.007,	r	=	0.01).	
Also,	decrease	in	T4	concentration	from	baseline	to	the	3	months	visit	in	the	two	groups	were	significant	
(p	=	0.000	in	both	groups).	In	patients	treated	with	RAI	only,	this	significant	decrease	was	observed	from	
between	the	2nd	and	3rd	visits	with	moderate	effect	(p=	0.000,	r	=0.341)	and	the	baseline	and	3rd	visits	
also	with	moderate	effect	size	(p	=	0.000,	r	=	0.428).	For	patients	who	received	both	RAI	and	lithium,	
significant	drop	in	T4	concentrations	were	observed	between	the	baseline	and	1	month	visit	with	small	
effect	size	(p	=	0.001,	r	=	0.287),	2nd	and	3rd	visits	also	with	small	effect	size	(p	=	0.000,	r	=	0.455)	and	the	
baseline	and	3rd	visits	which	showed	a	large	effect	size	(p	=	0.000,	r	=	0.579).	
3.3.1.	T4	concentration	and	Diagnosis	
	
Graves’	disease	
Figure	3.5	is	a	plot	of	free	T4	concentrations	over	time	for	patients	with	Graves’	disease	who	were	
treated	with	RAI	only	and	RAI	with	lithium.	
For	the	patient’s	diagnosed	with	graves’	disease,	there	was	no	significant	difference	in	freeT4	
concentration	between	the	two	groups	at	baseline	and	1	month	post	therapy.	The	difference	in	T4	
concentrations	at	3	months	between	the	RAI	only	and	RAI	with	adjuvant	Lithium	groups	was	significant	
(p	=	0.032,	r	=0.189).	
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Figure	3.5.	Mean	T4	concentration	across	the	3	visits	in	patients	diagnosed	with	Graves’	
disease.	
	
The	decrease	in	T4	concentration	across	the	3	visits	was	found	to	be	significant	in	the	two	groups	(RAI	
only	p=	0.000,	RAI	with	lithium,	p	=	0.000).	For	those	who	received	RAI	only,	the	significant	decrease	was	
noted	between	the	1month	and	3	months	visits	with	a	moderate	size	effect	(p	=	0.001,	r	=	0.365)	and	
between	the	baseline	and	3	months	visits	also	with	moderate	size	effect	(0.001,	r	=	0.427).	For	patients	
who	received	adjuvant	lithium,	significant	decrease	in	T4	concentration	was	noted	as	early	as	between	
baseline	and	1	month	visit	with	moderate	effect	size	(p	=	0.003,	r	=	0.283)	and	also	between	1	month	
and	3	months	visits	(p	=0.000,	r	=	0.464).	There	was	a	significant	decrease	with	a	large	size	effect	when	
we	considered	the	change	from	baseline	(37.657	pmol/l)	to	3	months	concentrations	(11.451	pmol/l)	(p	
=	0.000,	r	=0.597).	
Nodular	disease		
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Figure	3.6.	Mean	T4	concentration	across	the	3	visits	in	patients	diagnosed	with	nodular	
disease.	
	
There	is	no	statistically	significant	difference	in	T4	values	at	baseline,	1	month	or	3	months	between	
patients	who	took	RAI	with	adjuvant	lithium	and	those	who	had	RAI	only	(baseline	p	=	0.645,	1	month	p	
=0.471,	3	months	p	=0.149).	
Across	the	3	visits,	there	was	no	significant	difference	in	T4	concentration	in	patients	treated	with	RAI	
only	(p	=0.607).		However,	for	patients	who	received	adjuvant	Lithium	with	RAI	therapy,	there	was	a	
statistically	significant	difference	in	mean	T4	concentration	across	the	3	visits	(p	=	0.001);	seen	as	
decrease	in	mean	T4	concentration	from	baseline	of	22.060	pmol/l,	through	1	month	visit	(17.807	
pmol/l)	to		3	months	(11.013	pmol/l)	.	This	decrease	is	seen	between	the	1	month	and	3	months	visits	
with	moderate	size	effect	(p	=0.18,	r	=	0.4305)	and	baseline	and	3	months	visits	with	a	large	size	effect	
(p	=	0.006,	r	=	0.500).	
3.3.2. Neomercazole	Pretreatment	and	lithium		
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Table	3.5.	Mean	T4	concentration	across	the	3	visits	for	patients	who	received	Neormecazole	
pretreatment	and	those	who	did	not.	
	
	 	 RAI	Only	 RAI	+Lithium	
No	Pretreatment	 V1	 27.7146	 34.1042	
V2	 29.527	 20.690	
V3	 15.769	 10.384	
Neomercazole	
pretreatment	
V1	 33.377	 23.800	
V2	 24.498	 18.480	
V3	 18.480	 12.297	
	
Table	3.5	shows	the	mean	T4	concentration	during	each	of	the	3	visits	for	patients	who	received	
Neomercazole	pre-treatment	and	those	who	had	no	pre-treatment.	The	effects	of	pre-treatment	and	
lithium	on	T4	concentration	are	discussed	below.	
No	pretreatment	
There	was	no	significant	difference	in	mean	T4	concentration	between	those	who	had	RAI	only	and	
those	who	had	RAI	with	adjuvant	lithium	at	baseline	(p	=0.750)	and	at	1	month	(p	=	0.099).	There	was	
however	a	significant	difference	in	mean	T4	concentration	between	the	two	groups	at	3	months	with	a	
moderate	effect	size	(p	=	0.048,	r	=	0.320).	
For	the	patients	who	received	RAI	only,	there	was	no	significant	difference	in	mean	T4	concentration	
across	the	3	visits	(p	=	0.06)	in	contrast	to	those	who	received	RAI	with	adjuvant	lithium	who	showed	a	
significant	difference	(p	=	0.000).	This	difference	is	seen	as	a	decrease	in	mean	T4	concentration	from	
baseline	to	1	month	visit	(p	=	0.022,	r	=0.363),	1month	to	3	months	(p	=	0.000,	r	=	0.590)	and	from	
baseline	to	3	months	(p	=	0.000,	r	=	0.598).	
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Neomercazole	pretreatment.		
There	was	no	significant	difference	in	mean	T4	concentration	between	the	RAI	only	and	RAI	with	
adjuvant	Lithium	groups	during	all	3	visits	in	patients	pre-treated	with	Neomercazole	(p	=	0.910,	0.0702	
and	0.083	respectively).	
Both	groups	however	showed	significant	decrease	in	mean	T4	concentration	across	the	visits	(RAI	only	p	
=	0.002;	RAI	with	Lithium	p	=	0.000).	in	both	groups,	the	differences	are	noted	from	the	1month	to	3	
months	visits	and	also	the	baseline	to	3	months	visit	with	moderate	size	effect	in	patients	who	received	
RAI	only	(p	=	0.021,	r	=	0.265;	p	=	0.000,	r	=	0.473	respectively)	and	large	effect	size	in	patients	who	
received	RAI	with	adjuvant	Lithium	therapy	(p	=	0.000,	r	=	0.573	and	p	=0.000,	r	=	0.599	respectively).	
3.3.3. Gender	and	lithium		
Table	3.6	and	figure	3.7	illustrate	mean	T4	concentrations	of	males	and	females	over	the	3	visits	for	
patients	who	received	RAI	only	and	for	patients	who	received	RAI	with	adjuvant	lithium	therapy.	
Females		
Whilst	the	difference	in	mean	T4	concentration	at	baseline	and	1	month	between	the	RAI	only	and	RAI	
with	adjuvant	lithium	groups	remained	insignificant	(baseline	p	=	0.8291,	1	month	p	=0.8255),	the	
difference	at	3	months	however	was	significant	(p	=	0.0067)	with	T4	concentrations	being	lower	in	
patients	who	received	adjuvant	lithium	(11.398	pmol/l)	compared	with	RAI	only	(18.439	pmol/l)	
For	both	groups	of	patients	(i.e.	RAI	only	and	RAI	with	adjuvant	lithium),	the	observed	drop	in	T4	
concentration	from	baseline	through	to	the	3months	visits	were	significant	(RAI	only,	p	=0.000,	RAI	and	
lithium	=	0.0000).	For	patients	who	received	RAI	only,	these	were	observed	between	the	1	month	and	3	
months	visit	with	a	moderate	effect	size	(p	=	0.3105,	r	=	0.3105)	and	between	baseline	and	3	months	
also	with	a	moderate	effect	size	(p	=	0.000,	r	=	0.427).	In	the	patients	who	received	adjuvant	lithium	
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however,	significant	differences	were	noted	as	early	as	between	baseline	and	1	month	visits	with	
moderate	size	effect	(p	=	0.002,	r	=	0.275)	as	well	as	between	1	month	and	3	months	visits	(p	=0.000,	r=	
0.470)	and	baseline	and	3	months	visits	(p	=	0.000,	r	=	0.592)	with	moderate	and	large	effect	sizes	
respectively.	
	
Table3.6.	Mean	T4	concentration	across	the	3	visits	for	males	and	females.	
	
	 	 RAI	Only	 RAI	+Lithium	
Female	 V1	 34.98499	 35.0149	
V2	 24.739	 23.913	
V3	 18.439	 11.395	
Male		 V1	 27.2273	 33.2111	
V2	 31.363	 22.863	
V3	 12.850	 13.063	
	
Males		
There	is	no	significant	difference	in	T4	concentration	across	the	3	visits	in	both	the	RAI	only	and	RAI	with	
adjuvant	lithium	groups	in	male	patients	(p	=	0.66	in	RAI	only,	p	=	0.72	in	RAI	with	lithium).	
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Figure	3.7.	Mean	T4	concentration	across	the	3	visits	for	males	(M)	and	females	(F).	
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4. Discussion		
4.1.	Introduction	
Radioactive	iodine	therapy	has	been	shown	to	be	very	effective	in	hyperthyroidism	treatment.	The	goal	
of	radioiodine	therapy	as	earlier	discussed	is	the	return	of	patients	to	euthyroidism	either	with	or	
without	T4	replacement.	Advantages	of	radioactive	iodine	therapy	include	good	tolerability,	ease	of	
application,	safety	and	efficacy	of	therapy	(19,	20).	There	are	however	reports	of	poor	response	to	RAI	
therapy	in	some	patient.	Generally,	different	literature	reports	between	10	and	25%	treatment	failure	
between	Six	to	twelve	months	post	RAI	administration	(35,	48,	49).	We	set	out	in	this	study	to	increase	
the	efficacy	of	RAI	treatment	and	thus	reducing	incidence	of	treatment	failure	by	adding	adjuvant	
Lithium	to	the	RAI	therapy.		
4.2.	Cure	rate		
The	results	from	this	study	clearly	show	that	addition	of	adjuvant	lithium	to	RAI	therapy	is	beneficial	in	
the	treatment	of	hyperthyroidism.	It	clearly	demonstrated	that	a	higher	proportion	of	patients	(78.4%)	
who	received	adjuvant	lithium	were	cured	at	the	end	point	of	the	study	(three	months	after	RAI	
administration)	compared	to	those	who	received	RAI	only	(56%).		Lithium	treatment	resulted	in	an	
additional	22.4%	increase	in	cure	rate	3	months	post	RAI	therapy.	Our	findings	are	comparable	to	those	
from	Martin	et	al,	the	Pisa	group	and	Zha	et	al	(30,	35,	42,	44).	The	lower	proportions	of	cure	rate	
observed	in	our	study	compared	to	those	from	Martin	et	al	and	the	2	studies	from	the	Pisa	group	can	be	
attributed	to	the	shorter	end	point	of	3	months	in	our	study	compared	to	at	least	1	year	in	the	others.		It	
is	worthy	of	note	that	our	findings	contrasted		that	of	Bal	et	al	who	found	no	difference	between	the	RAI	
only	group	and	RAI	with	adjuvant	lithium	group	(43)	with	cure	rates	of	68.4%	and	68.9%	respectively.	
The	reason	for	the	lower	cure	rate	and	lack	of	difference	between	the	RAI	only	and	RAI	with	lithium	
groups	was	not	stated	and	was	more	likely	not	investigated	by	the	authors.	
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When	we	grouped	patients	according	to	their	diagnosis,	that	is,	Graves’	disease	and	nodular	disease,	we	
noted	a	trend	not	different	from	the	general	trends	discussed	above.	Graves’	disease	patients	who	
received	adjuvant	lithium	showed	a	significant	22.1%	increase	in	cure	rate	over	those	who	received	RAI	
alone	and	also	demonstrated	a	positive	association	between	Graves’	disease	and	adjuvant	lithium	and	
increased	cure	rates	in	Graves’	patients	who	received	RAI	therapy.	Though	patients	with	nodular	disease	
also	showed	a	similar	trend,	with	a	24%	increase	in	cure	in	patients	who	received	adjuvant	lithium	over	
patients	who	received	RAI	alone,	this	was	not	significant	statistically.	This	can	probably	be	explained	by	
the	small	number	of	nodular	disease	patients	who	enrolled	in	the	study	(total	of	30	with	14	receiving	RAI	
alone	and	16	receiving	RAI	with	adjuvant	lithium).	The	increased	cure	rate	in	nodular	patients	however	
is	corroborated	by	Martin	et	al	who	showed	that	adjuvant	lithium	doubled	the	chance	of	cure	with	RAI	
therapy	(42).	For	these	patients	in	particular,	this	finding	is	very	important	as	nodular	disease	patients	
generally	have	lower	cure	rates	and	a	higher	likelihood	for	retreatment	compared	to	Graves’	patients	
(6).	
Just	like	in	Graves’	patients,	our	female	patients	also	showed	a	positive	association	with	increased	cure	
rates	with	adjuvant	lithium	therapy.	This	was	seen	in	the	25.4%	increase	in	cure	rate	over	females	who	
received	RAI	only.	In	the	male	patients	however,	we	failed	to	demonstrate	any	positive	association	of	
lithium	therapy	with	cure	3	months	post	therapy.	Though	a	slightly	higher	percentage	of	patients	who	
received	adjuvant	lithium	got	cured	(77.5%)	compared	to	those	who	received	RAI	alone	(72.7%),	this	
was	not	statistically	significant.	The	lack	of	significance,	just	like	in	the	patients	with	nodular	disease	
could	be	related	to	the	small	number	of	male	patients	involved	in	the	study	(20	patients	in	total).	
The	cure	rates	achieved	in	our	study	(56%	for	RAI	only	and	78.4%	in	those	receiving	RAI	with	adjuvant	
Lithium)	were	found	to	be	generally	lower	compared	to	those	achieved	in	similar	studies,	which	had	
cure	rates	greater	than	80%	(30,	35,	42,	44).	This	however	can	be	explained	by	the	fact	that	our	study	
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had	a	shorter	endpoint	of	3	months	post	RAI	therapy	in	comparison	to	the	other	studies	where	follow-
up	lasted	at	least	a	year	post	therapy.		We	defined	cure	in	our	study	using	TSH	values.	It	is	however	
known	that	changes	in	TSH	after	RAI	therapy	usually	lags	behind	changes	in	T4	and	T3	concentration	and	
hence	given	time,	more	patients	are	likely	to	achieve	cure	as	observed	in	the	other	studies	with	longer	
follow-up	periods.	For	patients	receiving	RAI	only,	our	findings	of	cure	rates	of	55.7%	for	Graves’	
patients	and	57%	in	nodular	disease	patients	was	not	so	different	from	the	50%	cure	at	3	months	seen	in	
Graves’	patients	(35)	or	the	55%	cure	rate	at	3	months	in	toxic	multinodular	disease	(6).		
4.3. Time	to	cure	
Our	study	showed	that	12.9%	more	of	patients	who	had	adjuvant	Lithium	therapy	received	cure	1	
month	post	RAI	therapy	compared	to	those	who	received	RAI	only.	This	trend	towards	statistical	
significance	showed	by	this	finding,	together	with	the	fact	that	at	3	months,	78.4%	of	patients	who	
received	adjuvant	lithium	compared	to	only	56%	of	patients	who	had	RAI	alone	were	cured	supports	the	
theory	that	adjuvant	lithium	leads	to	prompter	control	of	hyperthyroidism.		Our	findings	were	in	
agreement	with	those	of	Martin	et	al	and	the	Pisa	group	who	both	found	significant	reduction	in	time	to	
cure	in	their	studies	(30,	42).	A	later	study	by	the	Pisa	group	also	supported	our	results	as	they	found	
that	50%	of	patients	who	received	adjuvant	lithium	were	cured	in	2	months	compared	to	RAI	only	group	
who	had	50%	cured	in	3	months	(35).	
This	prompter	control	of	hyperthyroidism	is	likely	due	to	the	fact	that	release	of	organic	iodine	as	well	as	
thyroid	hormones	are	blocked	by	Lithium	without	affecting	RAIU	by	the	gland	(30,	44).	In	fact	Plazinska	
et	al	even	went	further	to	show	that	adjuvant	lithium	is	able	to	increase	thyroidal	radioiodine	uptake	in	
patients	with	a	low	baseline	RAIU,	that	is	RAIU	less	than	30	(52).		Zha	et	al	also	found	that	in	patients	
treated	with	adjunct		lithium	during	RAI	therapy,	the	mean	radiation	absorbed	dose	rate	in	the	anterior	
neck	was	significantly	higher	than	that	with	RAI	alone	(44).	Adjunct	lithium	can	increase	radiation	dose	
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to	the	thyroid	by	an	average	of	39%	(45).	All	the	above	together	leads	to	a	prolonged	effective	half-life	
of	I-131,	leading	to	a	more	effective	action	of	dose	administered.	One	study	showed	effective	half-life	
was	prolonged	significantly	by	a	factor	of	1.61	+/-	0.49	in	patients	who	received	adjuvant	lithium	(45)	
This	finding	is	very	significant	because	of	the	immense	benefits	of	early	control	of	hyperthyroidism,	
especially	in	the	elderly	and	patients	with	concomitant	cardiovascular	diseases	who	require	rapid	
restoration	to	euthyroidism	(with	or	without	T4	replacement).	Also,	patients	receiving	RAI	often	
complain	of	unpleasant	symptoms	because	of	unstable	thyroid	hormone	levels	until	cure	is	achieved.	
Therefore,	adjuvant	lithium	shortening	time	to	cure	even	by	a	few	weeks	may	reduce	these	fluctuations	
in	hormone	concentration	and	will	be	of	great	clinical	benefit	to	most	recipients	of	RAI.	
4.4. T4	concentration	
According	to	the	American	Thyroid	Association	(ATA)	guidelines	(2011)	on	management	of	
hyperthyroidism,	RAI	therapy	is	repeated	if	hyperthyroidism	continues	6	months	after	initial	RAI	or	there	
is	minimal	response	3	months	after	the	initial	RAI	(6).	Since	TSH	levels	may	remain	suppressed	for	a	
month	or	longer	after	resolution	of	hyperthyroidism,	the	levels	are	usually	interpreted	together	with	
serum	free	T4	and	T3	in	order	to	select	patients	who	may	require	repeat	treatment	with	RAI.	
Our	study	showed	that	though	baseline	T4	values	were	similar	in	both	RAI	only	and	RAI	with	adjuvant	
Lithium	groups,	there	was	a	significant	difference	between	the	2	groups	at	3	months	post	therapy	as	
illustrated	in	figure	3.4	in	the	previous	chapter,	with	patients	who	received	adjuvant	Lithium	having	
lower	T4	concentration.	
It	is	also	worthy	of	note	that	our	study	not	only	demonstrated	a	significant	decrease	in	seumT4	
concentration	at	3	months	for	patients	who	received	adjuvant	lithium,	but	also	showed	a	significant	
decrease	from	baseline	T4	concentration	1	month	post	RAI	therapy	albeit	with	a	small	effect	size.	This	
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however	was	not	observed	in	patients	who	received	RAI	alone	as	the	decrease	in	T4	observed	in	this	
group	was	statistically	insignificant.	Even	more	remarkable	was	the	finding	that	at	3	months,	the	drop	in	
serum	T4	concentrations	from	baseline	values	in	patients	who	had	adjuvant	lithium	was	of	a	large	effect	
size	whilst	those	who	received	RAI	only	were	only	of	moderate	effect.		
The	above	goes	to	reiterate	the	fact	that	adjuvant	Lithium	significantly	reduces	serum	T4	concentration	
throughout	the	study.		This	is	achieved	by	inhibition	of	T4	release	from	the	thyroid.	Lithium	also	is	
known	to	prevent	deiodination	whilst	optimising	thyroidal	iodine	uptake(36).	These	findings,	especially	
that	of	a	significant	drop	in	T4	concentration	1	month	post	therapy	is	very	essential	in	the	elderly	and	
patients	with	cardiovascular	disease	as	discussed	earlier.	These	will	help	prevent	some	complications	
such	as	thyroid	storm	that	may	arise	due	to	release	of	preformed	T4	from	destruction	of	thyroid	follicles	
as	a	result	of	RAI	therapy.	
We	have	discussed	earlier	in	our	literature	review	some	of	the	several	factors	which	influence	early	
hypothyroidism,	or	put	in	another	way,	affect	persistence	of	hyperthyroidism	after	RAI	therapy.	These	
include	the	diagnosis	or	cause	of	hyperthyroidism,	gender,	pre-treatment	with	antithyroid	drugs	(ATDs),	
dose	of	RAI	used,	age,	RAIU	and	others.	We	tried	to	observe	changes	in	serum	T4	concentration	with	
adjuvant	lithium	in	the	presence	of	some	of	these	factors.	Our	findings	are	discussed	below.	
4.4.1.	T4	and	Diagnosis	
Our	findings	in	Graves’	patients	were	generally	a	mirror	of	the	response	of	T4	concentration	to	adjuvant	
lithium	as	discussed	earlier	above.		Patients	who	received	adjuvant	lithium	therapy	had	a	significantly	
lower	mean	T4	concentration	3	months	post	therapy	compared	to	the	RAI	only	group.	Also,	though	both	
groups	showed	a	significant	drop	in	T4	concentrations	at	3months	from	the	baseline	values,	we	showed	
that	this	decrease	was	large	in	the	adjuvant	lithium	group	compared	to	the	RAI	only	group	which	
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showed	a	moderate	decrease.	Even	of	greater	importance	was	the	fact	that	at	1	month	post	RAI	
therapy,	the	adjuvant	lithium	group	showed	a	significant	decrease	in	T4	concentration	which	was	of	
moderate	effect	size.		
The	above	findings	hence	goes	to	support	the	concept	that	adjuvant	Lithium	in	Graves’	disease	patients	
is	associated	with	increased	cure	rate	and	also	prompter	response	to	RAI	treatment.	
In	the	patients	with	nodular	disease,	we	found	no	significant	difference	in	the	mean	T4	concentrations	
between	the	two	study	groups	neither	at	1	month	nor	3	months.	However,	there	was	a	significant	drop	
in	T4	concentration	at	3	months	from	baseline	values	in	the	patients	who	received	adjuvant	lithium.	This	
was	not	observed	in	the	RAI	only	group.	
Our	findings	may	suggest	that	adjuvant	lithium	therapy	potentiates	effects	of	RAI	therapy	in	
hyperthyroid	patients	with	nodular	disease.	This	can	be	explained	with	our	earlier	finding	of	higher	cure	
rates	(albeit	an	insignificant	finding)	in	nodular	disease	patients	who	received	adjuvant	Lithium	and	our	
current	discussion	on	the	effects	of	adjuvant	Lithium	on	mean	T4	concentration	as	we	had	observed	.	
When	both	observations	are	considered	together,	we	can	deduce	that	much	more	nodular	patients	may	
have	resolution	of	hyperthyroidism	without	the	need	for	repeat	RAI	treatment	if	patients	were	allowed	
more	time	for	TSH	levels	which	always	lag	behind	changes	in	T4	concentration,	to	respond	and	rise.	
Hence	it	is	more	beneficial	monitoring	such	patients	with	their	serum	T4	rather	than	TSH	concentration.	
4.4.2. T4	Concentration	and	antithyroid	drug	pretreatment	
It	is	common	to	have	patients	pre-treated	with	antithyroid	medications	prior	to	RAI	therapy.	Even	in	
patients	who	RAI	therapy	has	been	decided	on	as	the	definitive	treatment,	antithyroid	drugs	may	be	
initiated	especially	when	T4	values	are	high	and	patient	shows	signs	and	symptoms	of	thyrotoxicosis	to	
reduce	thyroid	hormone	toxicity	before	RAI	therapy.	Thionamides	which	includes	Neomercazole	
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(carbimazole)	the	preferred	drug	of	choice	in	our	institution,	and	Propylthiouracil	are	the	main	
antithyroid	drugs	in	use.	
Earlier	treatment	with	some	antithyroid	drugs	like	Propylthiouracil	may	be	linked	with	a	higher	rates	of	
treatment	failure	but		Andrade	et	al	came	to	the	conclusion	that	methimazole	(a	thionamide)	pre-
treatment		did	not	interfere	with	the	final	outcome	(41,	53).	It	has	been	proposed	that	the	radio-
resistance	associated	with	propylthiouracil	and	thioureases	in	general	is	as	a	result	of	the	presence	of	a	
sulfhydryl	group,	which	is	absent	in	the	thionamides	(methimazole	and	carbimazole)	(53).	This	may	
explain	the	lack	of	interference	of	RAI	with	thionamide	pre-treatment.	Therefore	these	drugs	are	usually	
withdrawn	before	RAI	therapy;	4	–	7	days	for	thionamides	and	at	least	2	weeks	for	propylthouracil.	
We	attempted	to	find	out	if	pretreatment	with	neomercazole	had	any	effect	of	T4	concentrations	in	our	
study.	
We	discovered	that	there	was	no	difference	between	mean	T4	concentrations	amongst	the	two	groups	
at	3	months	in	patients	pre-treated	with	Neomercazole.	Both	groups	however	showed	significant	
decrease	in	T4	concentration	at	3	months	compared	to	baseline.	These	decreases	were	shown	to	be	of	a	
large	effect	in	the	adjuvant	Lithium	group	in	comparison	to	the	RAI	only	group	which	showed	moderate	
effect	size.		This	shows	that	adjuvant	lithium	may	have	an	effect	on	T4	concentrations	in	patients	pre-
treated	with	Neomercazole.	This	effect	likely	due	to	the	inhibition	of	the	increased	T4	release	that	
results	from	the	Neomercazole	withdrawal	both	before	and	after	RAI	therapy	(41).	
For	the	patients	who	had	no	pretreatment,	we	observed	that	the	adjuvant	Lithium	group	showed	
significantly	lower	T4	concentrations	than	the	RAI	only	group	at	3	months.	There	was	also	a	significant	
reduction	in	mean	T4	concentration	at	1	month	and	also	at	3	months	from	baseline	in	patients	who	
received	adjuvant	Lithium.	This	observation	however	was	absent	in	the	RAI	only	group.	
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Our	observations	show	that	adjuvant	Lithium	therapy	had	the	greatest	effect	of	lowering	mean	T4	
concentration	in	patients	who	did	not	receive	pretreatment	with	Neomercazole.	We	also	observed	that	
in	general,	T4	concentration	in	patients	who	did	not	receive	pretreatment	with	neomercazole	showed	
better	response	to	RAI	therapy	with	greater	reduction	from	baseline	levels	compared	to	patients	who	
received	Neomercazole.	
4.4.3. T4	Concentration	and	gender	
As	expected,	we	found	that	females	who	had	RAI	with	adjuvant	Lithium	had	significantly	lower	T4	
concentrations	at	the	end	of	the	study	compared	to	those	who	had	RAI	alone	and	also	showed	a	
significant	decrease	from	baseline	values	as	early	as	1	month	post	therapy.	Though	both	groups	showed	
decreases	at	3	months	from	baseline,	the	decrease	amongst	the	adjuvant	Lithium	group	was	of	larger	
effect.	The	above	strengthens	our	earlier	finding	of	a	strong	association	between	females	receiving	
adjuvant	Lithium	therapy	and	increased	cure	rates	post	RAI	therapy.	It	also	supports	the	position	of	
prompter	response	to	RAI	therapy	with	adjuvant	lithium	therapy	and	hence	earlier	resolution	of	
hyperthyroidism,	considering	the	significant	decrease	in	T4	from	baseline	values	observed	at	1	month	
post	therapy.	
The	male	patients	on	the	other	hand,	showed	no	significant	differences	in	T4	concentration	between	the	
2	groups	at	the	end	of	the	study.	There	was	also	no	significant	decrease	in	T4concentration	from	
baseline	at	the	end	of	the	study.	As	was	pointed	out	earlier	whilst	discussing	the	cure	rates	in	males,	this	
lack	of	difference	observed	may	be	due	to	the	smaller	numbers	of	male	patients	involved	in	the	study.	
This	makes	it	very	difficult	to	make	any	meaningful	statistical	deductions	from	the	study	with	this	group.	
Also,	some	studies	have	suggested	male	gender	as	a	factor	affecting	poor	response	to	RAI	therapy	(13).	
Allahabadia	et	al	found	that	males	had	a	significantly	lower	cure	rate,	after	one	dose	of	radioiodine,	than	
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females	(13).	However,	there	are	others	who	found	no	significant	difference	in	outcomes	between	
males	and	females	post	RAI	therapy	(29).	
4.5. Lithium	adverse	effects	
In	our	study,	patients	received	800mg	of	Lithium	per	day	for	7	days	starting	on	the	day	of	RAI	therapy.	
Only	1	patient	out	of	the	initial	185	(0.5%)	patients	recruited	complained	of	symptoms	in	keeping	with	
lithium	toxicity	and	hence	was	excluded	from	the	study.	The	patient	phoned	into	the	department	and	
complained	of	diarrhoea	a	day	post	RAI	and	was	advised	to	stop	the	lithium	immediately.	The	low	
incidence	of	side	effects	can	be	attributed	to	a	considerably	lower	dose	regimen	and	shorter	period	over	
which	it	was	administered	compared	to	previous	studies	(35,	43).	Even	in	the	a	previous	study	where	
900mg	of	adjuvant	lithium	per	day	was	given	for	12	days,	occurrence	of	side	effects	were	insignificant	to	
limit	its	usage(35).	Hence	with	our	lower	dose,	it	is	safe	to	assume	that	these	patients	should	remain	
free	of	adverse	effects.	
4.6. Loss	to	Follow-up	
Of	worry	was	the	number	of	patients	who	were	lost	to	follow-up.		About	5%	(10	out	of	185)	of	the	initial	
patients	recruited	were	lost	to	follow-up.	What	made	this	even	more	worrying	was	the	fact	that	we	
made	it	a	duty	to	call	all	patients	and	remind	them	of	their	laboratory	appointments	the	week	they	were	
due,	after	we	fail	to	locate	any	results	for	them	on	the	NHLS	Trackcare	system.	This	shows	that	a	lot	
more	patients	could	have	ended	up	defaulting	if	not	for	the	calls	we	placed	to	them.	These	patients	
would	be	at	risk	of	severe	complication	especially	those	who	become	hypothyroidal	and	those	who	
remain	hyperthyroidal	as	a	consequence	of	treatment	failure.	
4.7. Limitations	of	study	
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The	study	did	not	evaluate	serum	free	T3	concentration.	This	was	because	most	patients	did	not	have	
results	for	T3	because	of	the	gatekeeper	policy	of	the	NHLS.	It	would	have	been	interesting	to	see	the	
correlation	between	T3	and	T4	concentrations	in	the	different	scenarios	we	analysed.	There	may	also	
have	been	patients	with	T3	toxicosis	who	may	have	presented	with	normal	T4	levels.	These	patients	we	
would	have	failed	to	detect.	
Problems	with	supply	of	1-131	for	long	periods	during	the	study	as	well	as	other	logistical	problems	
beyond	the	power	of	us	the	investigators	led	to	prolongation	of	the	projected	timelines	and	as	a	result,	
delay	in	the	completion	of	the	study.	This	also	prevented	us	from	reaching	the	projected	mark	of	200	
patients	for	the	study	as	was	initially	planned.	
4.8. Application	of	Knowledge	
The	fact	that	low	dose	short	course	adjuvant	lithium	therapy	has	minimal	side	effect	but	significantly	
improves	the	efficacy	of	RAI	therapy	in	hyperthyroid	patients	compels	us	to	advocate	for	its	inclusion	in	
the	management	of	hyperthyroid	patients,	especially	those	with	serious	risk	of	increased	complications	
from	hyperthyroidism	such	as	the	elderly	and	patients	with	pre-existing	cardiac	problems.		
We	also	showed	that	T4	concentration	in	patients	who	did	not	receive	antithyroid	drug	pretreatment	
responded	better	to	RAI	therapy.	We	therefore	suggest	patients	in	whom	RAI	therapy	has	been	decided	
as	1st	line	especially	to	be	sent	for	their	dose	of	RAI	early	and	avoid	Neomercazole	pretreatment	if	
possible	so	as	to	improve	cure	rates.		
4.9. Future	research	
Further	research	needs	to	be	carried	out	in	male	patients	and	patients	with	nodular	disease	with	a	larger	
sample	size,	so	as	to	get	more	robust	data	on	these	two	groups	of	patients.	Our	group	also	may	request	
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an	extension	of	the	Ethics	permission	to	assess	the	status	of	all	the	study	participants	at	12	month’s	
period	from	the	time	of	RAI	administration.	
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5. Conclusion		
A	summary	of	our	major	findings	are	highlighted	below.	
1. Adjuvant	lithium	therapy	increases	efficacy	of	radioactive	iodine	treatment	in	hyperthyroidism	
by	increasing	overall	cure	rate	and	also	shortening	the	time	to	cure.	
2. There	was	a	positive	association	between	adjuvant	lithium	therapy	and	increased	cure	rate	in	
Graves’	patients.	These	patients	also	showed	a	prompter	response	to	therapy.	
3. Though	there	was	a	statistically	insignificant	increase	in	cure	rate	in	patients	with	nodular	
disease	who	received	adjuvant	lithium,	the	clinically	significant	drop	in	T4	concentration	at	the	
end	of	the	study	from	baseline	values	suggests	adjuvant	Lithium	potentiates	the	effect	of	RAI	
therapy	in	this	group	of	patients.	
4. There	was	a	positive	association	of	adjuvant	lithium	with	increased	cure	in	female	
hyperthyroidal	patients.	This	observation	however	was	not	present	in	male	patients.	
5. Adjuvant	lithium	was	also	shown	to	significantly	reduce	serum	free	T4	concentration	following	
RAI	therapy.	
6. Reduction	in	serum	free	T4	concentration	post	RAI	therapy	from	baseline	values	were	higher	in	
patients	who	were	not	pre-treated	with	Neomercazole	than	those	who	received	pretreatment.	
Also,	adjuvant	Lithium	therapy	was	shown	to	further	reduce	T4	concentration	post	RAI	in	those	
patients	who	did	not	receive	pretreatment.	
7. Low	dose	short	course	Lithium	therapy	resulted	in	very	minimal	side	effects	and	therefore	safe	
to	use	as	an	adjunct	to	RAI	therapy.	
5.1.	Recommendations	
From	our	findings,	we	recommend:	
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• Addition	of	adjuvant	lithium	to	RAI	treatment,	especially	in	those	patients	with	Grave’s	disease	
and	at	risk	of	increased	cardiac	complications	and	the	elderly.	
• Decision	to	treat	patients	with	RAI	should	be	made	as	early	as	possible	after	diagnosis	to	
minimise	the	impact	of	antithyroid	medications.	
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Appendix	A:	Data	collection	sheet	
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Appendix	B:	Ethics	Clearance	Certificate		
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Appendix	C:	Patient	information	and	consent	form	
	
Comparing	the	effect	of	adjuvant	lithium	therapy	on	the	efficacy	of	radioactive	iodine	therapy	in	
hyperthyroidim.	
Good	day	
My	name	is	Dr	E.	Nii	Boye	Hammond	of	the	Nuclear	Medicine	Department	of	Charlotte	Maxeke	
Johannesburg	Academic	and	Chris	Hani	Baragwanath	Academic	hospitals.	I	am	conducting	a	research		
comparing	the	effect	of	adjuvant	lithium	therapy	on	the	efficacy	of	radioactive	iodine	therapy	in	
hyperthyroidism.	Research	is	just	the	process	to	learn	the	answer	to	a	question.	In	this	study	we	want	to	
learn	if	giving	patients	Lithium,	in	addition	to	radioactive	iodine	therapy	can	help	improve	cure	rates	and	
prevent	further	treatment	of	their	hyperthyroidism.				
I	am	inviting	you	to	take	part	in	this	research	study.	
What	is	involved	in	the	study:	
In	addition	to	the	radioactive	iodine	treatment	you	have	been	referred	for,	you	would	be	receiving	
lithium	carbonate	tablets	which	you	would	be	taking	orally	800mg	daily.	Routine	follow-up	and	
laboratory	tests	would	be	done	as	per	the	normal	clinical	protocol.	
Study	procedure:	
Patients	in	this	study	will	be	randomly	selected	and	put	into	two	parallel	groups;	one	receiving	fixed	
dose	of	10mCi	radioactive	iodine-131	only	(with	no	additional	treatment)	and	the	other	group	receiving	
fixed	dose	of	10mCi	radioactive	iodine-131	plus	Lithium	carbonate	(800mg)	daily	for	7	days,	starting	
from	day	of	RAI	administration.	
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Risks	of	being	involved	in	this	study:	
Though	very	rare,	there	are	few	side	effects	associated	with	lithium	administration	which	includes	
gastrointestinal	discomfort,	nausea,	diarrhea,	polyuria,	weight	gain;	skin	eruptions,	alopecia,	and	edema	
are	common.	More	rare	side	effects	are	tremor,	poor	concentration	and	memory,	ataxia,	dysarthria,	and	
incoordination.		However,	the	dose	of	lithium	we	are	administering	for	the	study	is	below	the	normal	
therapeutic	levels,	and	also	for	a	very	short	period	(7	days),	therefore	we	do	not	anticipate	any	
significant	effects.	
Benefits	of	being	in	the	study:	
Your	participation	will	help	us	to	find	out	how	effective	this	treatment	regime	is	and	also	decide	if	future	
patients	should	be	made	to	follow	this	treatment	protocol.	
Your	participation	is	voluntary.	
Should	you	choose	not	to	participate,	this	will	not	change	the	way	we	treat	you	in	any	manner.		
Confidentiality:		
Efforts	will	be	made	to	keep	personal	information	confidential.			
Contact	details	of	researcher:	
	For	further	information,	please	do	not	hesitate	to	contact	me,	Dr	E.	Nii	Boye	Hammond	on,	on	011	488	
3559	or	011	9338502	
In	case	you	have	any	concerns,	you	may	contact	the	Ethics	Committee	at	011	717	1234		
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I	have	read	the	information	provided	for	the	as	described	above.		My	questions	have	been	answered	
to	my	satisfaction,	and	I	agree	to	participate	in	this	study.		I	have	been	given	a	copy	of	this	form.	
	
______________________________________																																		Tel	No:	
Name	of	Participant	(please	print)	
	
______________________________________	 	 	 ______________	
Signature	of	Participant	or	Legal	Representative		 	 Date	
	
SIGNATURE	OF	WITNESS	
	
______________________________________	
Name	of	Witness	(please	print)	
	
	
_____________________________________	 	 	 _______________	
	 Signature	of	Witness	 	 	 	 	 	 Date	
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Appendix	D:	“Turnit	in”	report	
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